

COURTESY OF
KGH ARCHIVES

QUEEN'S UNIVERSITY
DEPARTMENT OF PATHOLOGY



FACULTY OF MEDICINE
ANNUAL REPORT
1997

DR. PAUL MANLEY, M.D. - CHAIRMAN

**DEPARTMENT OF PATHOLOGY
1997
ANNUAL REPORT**

TABLE OF CONTENTS

Introduction

Faculty, Administration and Laboratory Managers and Supervisors

Laboratory Medicine and Pathology

Clinical Laboratories of Eastern Ontario (CLEO)

Personnel, Awards and Significant Events

Undergraduate, Graduate and Postgraduate Educational Programs

Research Projects and Grants in Progress

Department of Pathology Visiting Lecturers

Senior Staff Department of Pathology and Queen's University Lectures

Senior Staff Department of Pathology
Invited Lectures Outside of Kingston

Senior Staff Committees

Editorial Boards and Grant Review Committees

Full Papers Published and in Press

Abstracts

(Report written March 1998)

*FACULTY, ADMINISTRATION
AND
LABORATORY MANAGERS AND SUPERVISORS*

**DEPARTMENT OF PATHOLOGY
FACULTY**

1997-98

PROFESSOR AND HEAD

Dr. Paul Manley

PROFESSORS

Dr. A.F. Clark*

Dr. S. Cole

Dr. R. Deeley

Dr. G. Delisle*

Dr. A.M.V. Duncan (resigned June 30, 1997)

Dr. B. Elliott

Dr. A.R. Giles

Dr. J.C. Kennedy*

Dr. R. Kisilevsky

Dr. D. Lillicrap

Dr. S. Ludwin

Dr. P.G. Young*

ASSOCIATE PROFESSORS

Dr. B. Campling*

Dr. D. Dexter

Dr. W.A. Fletcher

Dr. S. Ford

Dr. P. Greer

Dr. L. Mulligan*

Dr. M. Petkovich*

Dr. L. Raptis*

Dr. M. Richardson

Dr. L. Tomalty

Dr. S. Wasan

Dr. I. Young

ASSISTANT PROFESSORS

Dr. A.S. Boag

Dr. C. Collier

Dr. S. Davey*

Dr. G. Evans*

Dr. K. Harrison

Dr. D. Hurlbut

Dr. M. Khalifa*

Dr. D. LeBrun

Dr. D. Lee*

Dr. D. Maurice

Dr. C. Mueller*

Dr. D. Rapson (0.5 part-time)

ASSISTANT PROFESSORS
(cont'd)

Dr. M. Raymond
Dr. J. Rossiter
Dr. C. Rowlands
Dr. S. SenGupta
Dr. L. Shepherd
Dr. S. Taylor
Dr. D. Zoutman

LECTURER

Dr. J. Raymond

**ADJUNCT ACADEMIC
GROUP I**

Dr. L. Becker
Dr. S. Birse
Dr. A. Duncan
Dr. M. Gaber
Dr. S. Inoue
Mr. L. Kennedy
Dr. D.M. Robertson, Emeritus
Dr. J. Samis
Dr. P. Turner
Dr. G. Twemlow

ADMINISTRATION

Laboratory Manager	- Mr. David Piper
Administrative Assistant	- Mrs. Marg McIlroy

**LABORATORY MANAGERS
AND SUPERVISORS**

Anatomic Pathology	- Mr. Dave More
Chemistry	- Mrs. Mary Waugh
Cytogenetics	- Ms. Anne Hanley
Microbiology	- Ms. Linda Fidler
CLEO	- Mr. Dave More

***Cross-Appointed Staff**



June 1997

Back Row: (From left to right) - S. Boag, I. Young, A. Duncan, J. Rossiter, D. Hurlbut, D. Zoutman M. Rutherford, D. LeBrun and J. Kennedy

Middle Row: - A. Lee, C. Collier, D. Rapson, S. SenGupta, D. Kydd, L. Kennedy, J. Vu, K. Chan, D. D'Costa (summer student), J. Raymond and D. Stather (summer student)

Front Row: - D. Lillicrap, A. Giles, S. Wasan, P. Manley, S. Ludwin, S. Cole, M. Raymond and A. Fletcher

COURTESY OF
KGH ARCHIVES

*LABORATORY MEDICINE
AND
PATHOLOGY*

INTRODUCTION & EXECUTIVE SUMMARY

The nature of Pathology as a discipline is special, as the subject bridges the interface between basic medical science and clinical practice.

Therefore the role of the Queen's Department of Pathology is distinctive at the Medical School, in that while playing a major role in the educational and research aspects of the school, it functions as both a basic science and a clinical department; at the same time it is responsible for one of the most technically and administratively complex service departments in the affiliated hospitals.

The Department has achieved excellence in many areas of its mandate, by building on a policy of commitment to academic excellence, while at the same time taking into consideration the unique features offered by the local Queen's and regional environments. Of great importance in achieving this aim has been the establishment of a common set of values throughout the Department, in which mutual respect for excellence in all of the various aspects of Departmental work has been achieved among its members, and in which there has been little internal dissention about the need to mutually support the various diverse endeavours of the Department. In these endeavours, the strategic plan of the Department, and its vision are remarkably consonant with the recently articulated Vision Statement elaborated by the new Dean of Medicine.

The educational aspects of the Department have traditionally been very strong. The Pathology Department is unique in that it offers a complete range of educational facilities, from Undergraduate Medical, Undergraduate Life Sciences and Graduate Studies, to Postgraduate Resident levels. The evolution of teaching to Undergraduate Medical students has progressed from the delivery of traditional courses in General and Special Pathology under the old curriculum, to the integrated teaching of the new curriculum, a process still in progress, but one which has been readily embraced by the Department, which has shown a willingness to take a leadership role in the process. The Undergraduate Life Science programme has progressively expanded at Queen's, and concurrent with this, the enrolment in courses given by the Pathology Department has steadily increased. The Pathology Department is actively pursuing, together with other Basic Science departments, methods of collaborative teaching in this important programme. The Department's Graduate Studies programme has increased dramatically since its inception, with a major increase in a number of Graduate students studying and doing research within the Department.

Traditionally, residency training in the Department has been very strong, with 4 programmes accredited by the Royal College of Physicians of Canada being offered. Queen's graduates have had a remarkably high rate of success in examinations in these programmes, and have gone on to take jobs in both the Academic and the Non-University sectors. The General Pathology training programme for years has been considered one of the best of its kind in the country, and the Neuropathology training programme has attracted applicants from around the world, who have then gone on to important academic positions in the country. The Pathology training programme like those all around the country faces tremendous challenges due to the recent restrictions on positions and entry imposed by the Provincial governments.

Since the 1950's, the Department, starting under the Headship of Dr. Robert More, has developed into an extremely strong academic unit. Although the Department is of relatively small size, in concert with the size of Queen's Medical School and the affiliated hospitals, (see comparatives for some figures) it has achieved a level of academic excellence, far in excess of that expected for its numbers. The Department attracts external funding of approximately \$2.7 million annually, in competitive grants, a figure among the highest in the Medical School in absolute terms, and by far the highest on a per FTE basis. (It should be pointed out that this figure covers only those

Faculty members having a Primary appointment in Pathology - those with joint appointments in Pathology whose home department is elsewhere are not included in these statistics). As can be seen by the reference to the comparator medical schools, this is a record which puts the Department at the top rank of departments across Canada. Pathology Department researchers have 4 times within the last 10 years won the University-wide Excellence in Research Award, a record unmatched by any other university department. Research groupings in the Department, in Cancer, Haemostasis, Amyloidosis, Neuroscience and Human Genetics have been well established, with multiple links to researchers in other departments across the university, and internationally.

The service aspects of the Department take place mainly in the affiliated hospitals, Kingston General and Hotel Dieu. Together this forms an important component of the hospital budget and functioning. There is a complex administrative structure, which has traditionally encompassed 2 separate hospitals. With the restructuring taking place in the city of Kingston, within a few months this will be simplified with the formation of a single Department to be sited primarily at Kingston General Hospital. The clinical activities cover a wide range of specialist's and sub-specialist's expertise.

A major enterprise of a great practical and academic importance has been started with the introduction of the Clinical Laboratories of Eastern Ontario Regional Programme. This has been a landmark initiative, involving the provision of laboratory services, expertise and increasingly education by the Queen's academic department to the hospitals in the region of South Eastern Ontario. This exercise is a novel one, which is proving to serve as a model not only for other Academic Pathology Departments across the Province, but for Clinical Departments as well.

The Department is thus fulfilling the mandate of the new Dean's Vision Statement of the Medical School, in the Generation, Transmission and Application of knowledge. It has long concentrated on the training of excellent General Pathologists, while at the same time achieving international stature in the provision of selected sub-specialists' services. In the service and education sectors, the Department has served not only the entire local area, but has now embarked on an ambitious regional programme, taking into consideration the unique features of the South Eastern Ontario Health Sciences environment. In the field of research, or knowledge generation, international excellence has been achieved, through the formation of collaborative groups both within and outside the Department.

DEPARTMENT OF PATHOLOGY AND
DIVISION OF CLINICAL LABORATORIES
ANNUAL REPORT, FEBRUARY 1997

PREAMBLE

The Department of Pathology at Kingston General Hospital is:

- a) a medical department reporting through the Medical Advisory Committee
- b) the Division of Clinical Laboratories reporting through the Operations Executive

Our major function is to provide useful answers to clinical inquiries by performing laboratory testing for patients in a reliable and timely fashion, and when appropriate, providing interpretation or diagnosis of test results. We thus derive both our work and our strength from clinical departments.


Pathologists differ from most clinicians both in our authority and responsibility for the management of operational and capital budgets and of a large number of technical staff, and for our status as salaried employees. We are required to be competent middle level executives as well as clinical consultants and scholars.

FUNCTION AND SERVICES PROVIDED

- a) Provision of accurate, useful and timely laboratory information to Clinical Services within the hospital;
- b) Clinically related and basic research;
- c) Teaching:
 - Pathology resident staff and Queen's Medical, Arts & Science, Graduate, Nursing and Rehabilitation Science students
 - Clinical staff and their residents through interdepartmental conferences and quality assurance rounds such as Medical, Surgical and Pediatric Mortality conferences
 - Medical technologists from St. Lawrence College
 - Cytotechnologists from the Michener Institute for Applied Sciences
 - Fellows in Molecular Genetics and Cytogenetics
 - Technologists from DNA Technology at Michener Institute
- d) Direct management of area hospital laboratories - Napanee, Picton, Perth/Smiths Falls, St. Mary's, Ongwanada and MDS-Kingston;
- e) Eastern Ontario Reference Laboratory - above hospitals and Hotel Dieu Hospital, Belleville, Brockville, Cornwall, Trenton, Ongwanada and Winchester;
- f) Extramural professional consultations.
- g) Forensic Pathology consultations.
- h) Community laboratory with HDH in conjunction with the Hospitals-in-Common Laboratory, Napanee and Perth/Smith Falls.
- i) Kingston General Hospital is the National Reference Laboratory for hemostasis testing for the Association of Hemophilia Centre Directors of Canada and is providing surveillance information to the Canadian Blood Agency via that role.

COURTESY OF
KOH ARCHIVES

*PERSONNEL, AWARDS
AND
SIGNIFICANT EVENTS*



PERSONNEL, AWARDS AND SIGNIFICANT EVENTS

OAP

Dr. Sandip SenGupta began a two year term of office as the new President of the OAP.

Dr. Sandip SenGupta and Dr. Nav Gill shared the first prize award for their poster presentation at the OAP Annual Meeting, "The Changing Role of the Pathologist?"

Dr. Michael Rutherford shared the first prize award in the platform presentation category for his paper entitled "Expression of Transcription Factor E2A in Human Tissue".

AMERICAN COLLEGE OF PATHOLOGISTS

Dr. Alan Giles was invited to participate in a Consensus of Experts Conference on "The Monitoring of Anticoagulants."

CANADIAN COLLEGE OF MICROBIOLOGY

Dr. Lewis Tomalty obtained certification as Specialist in Clinical Microbiologist.

COMMUNITY & HOSPITAL INFECTION CONTROL ASSOCIATION OF CANADA

Dr. Dick Zoutman received this award for best abstract at the 1997 annual scientific meeting held in Quebec City.

PMAC/MRC AWARD

Dr. Donald Maurice has received the distinguished Pharmaceutical Manufacturing Association of Canada Health Research Foundation/Medical Research Council Career Award in Health Sciences Award, salary support for 1996-2001. Only one granted in Canada.

ONTARIO HEART AND STROKE FOUNDATION

Dr. Alan Giles has been the recipient of the Distinguished Research Professorship from 1989-1997.

Dr. David Lillicrap has been an Ontario Heart and Stroke Foundation Career Investigator since 1995.

ROBERT PRENTICE AWARD - RESIDENT PATHOLOGY TEACHING

Pathology Residents were pleased to present **Dr. David Hurlbut** with the Robert S.A. Prentice Award for excellence in teaching.

DURNEY FELLOWSHIP, NEURO ONCOLOGY FOUNDATION

Dr. Karen Harrison was selected as the recipient of this award which she declined.

MRCC

Dr. Peter Greer has received a Medical Research Council of Canada Scholarship from 1994-1999.

SYMPOSIUM ON LUNG CANCER

Dr. Susan Cole was a plenary speaker at the Symposium on Lung Cancer - New Aspects meeting in Vienna, Austria.

KUWAIT UNIVERSITY

Dr. Gloria Delisle visited KU to evaluate the doctoral program offered by the Department of Microbiology at the KU Faculty of Medicine. This program is the first doctoral program in medicine offered under the aegis of the College of Higher Studies.

RESIGNATION OF DR. ALESSANDRA DUNCAN

Dr. Alessandra Duncan resigned from Queen's University effective June 30, 1997. She has accepted a position at McGill University.

COURTESY OF
KGH ARCHIVES

*UNDERGRADUATE, GRADUATE
AND
POSTGRADUATE
EDUCATIONAL PROGRAMS*



UNDERGRADUATE, GRADUATE AND POSTGRADUATE EDUCATIONAL PROGRAMS

UNDERGRADUATE (Written by Mrs. Jean Guindon)

Phase I Pathology is given in the academic year from mid-November to mid-February to first year medical students. Enrolment is 75 students.

Phase II Pathology is given after Phase I to 2nd year medical students but not in a Pathological Unit as such, but rather as a course combined with many other disciplines. Enrolment is 75.

Rehabilitation Medicine 234 The Department coordinates with the School of Rehabilitation Therapy and teaches a Pathology unit to Occupational and Physical Therapy students. This section runs from mid-September to the end of October. Dr. SenGupta is the Coordinator and the lecturers are department residents. Enrolment runs between 50 and 75 students.

Pathology 410/824 is a half credit course running in the Fall term and offered to 4th year Life Science students combined with a graduate course for non-medical students. Dr. John Rossiter is the Coordinator. Enrolment for 1997 was 48 undergraduate students and 4 graduate students. Evaluation for undergraduate students includes a mid-term and final exam. Evaluation for graduate students includes a midterm exam, final exam and a term paper.

Pathology 420 is a full credit thesis project course. Dr. David Lillicrap is the Coordinator. Department faculty members supervise students on a year long thesis project. Evaluations include a draft thesis introduction, seminar presentation, project defence, laboratory work evaluation and a written thesis.

Pathology 430/826 is a half credit course that is offered alternate winters. Dr. John Rossiter and Dr. David Lillicrap are Coordinators. Four diseases are covered in depth, examining the molecular events leading to the development of these disorders. Enrolment is 12 with preference given to graduate students. Evaluation includes seminar presentations and written reports.

Pathology 811 is a half credit course that if offered yearly provided enrolment is sufficient. The aim of this course is to show how chromosomes are studied in relation to clinical medicine. Please note that this course has not run since 1992.

Pathology 823 is a half credit course in cancer biology that runs alternate years in the fall term. Dr. Bruce Elliott is the Coordinator. Evaluations include a presentation, essays and a final examination.

Pathology 825 is a half credit course offered alternate years in the winter term. This course studies normal and abnormal human genetic variations. Dr. Lois Mulligan is the Coordinator. Evaluation includes seminar presentations, a grant proposal and a final examination.

GRADUATE PROGRAMME: ANNUAL REPORT

The Graduate Programme in the Department of Pathology is administered by the Graduate Program Committee. The Committee consists of five members of the Department, one of whom is designated Co-ordinator, plus the Head of the Department (Dr. Paul Manley) and two graduate student representatives *ex officio*. Dr. Bruce Elliott co-ordinated the Program and chaired the Department of Pathology Graduate Committee during the current year. Other faculty members were Drs. Susan Cole, Samuel Ludwin, and Lois Mulligan. Dr. David Lillicrap's term on the Committee ended as of July 1, 1997; Dr. Susan Cole filled this position. The student representatives for 1996-97 were Ms. Carla Cuthbert and Mr. Jay White. For the 1997-98 academic year Ms Suzan Abu-Abed and Ms Kelly Wilton were nominated to these positions. The Committee met on a monthly basis to make decisions on admissions, review student progress, review membership of Master's and Doctoral theses committees and rate and recommend students for scholarships and awards.

Thirty-two students were registered during the calendar year 1997. Twelve were registered in the Doctoral Programme and 20 in the Master's Programme. Four Master's students (Stacey Ivanchuk, Lawrence Martens, Jennifer McVeigh, Eric Wooldtorton) and one Doctoral student (Ron Saulnier) defended their theses in 1997. Dr. Saulnier has a position as Postdoctoral Fellow at the University of Western Ontario under the supervision of Dr. David Litchfield. Mian Gao successfully defended his Mini-Master's examination to proceed to the PhD Programme. Carla Cuthbert successfully defended her comprehensive examination in February.

In 1997, approximately one third of these students were externally funded from provincial and federal funding agencies, eg. MRC, OGS, United States Army, as well as the Queen's Graduate Fellowship Programme. Within the Department, four students (Kurt Almquist, Megan Begbie, David Hipfner and Angela Keightley) received MRC Studentships; two held Ontario Graduate Scholarships (Yotis Senis and Sarah Ely); one PhD student (Ron Saulnier) was the recipient of a United States Army Fellowship (1996/97 academic year); and three students (1997/98) were successful in the Queen's Graduate Fellowship competition.

In the calendar year 1997 the Graduate Program processed approximately 175 requests for application material. The ratio of Canadian enquiries to those from other countries is approximately 3:4.

RECRUITMENT INITIATIVES:

During the past year, the Department has increased its recruitment profile in several respects. In addition to the annual Department of Pathology evening for Health Sciences students held in the Fall, Pathology is now represented at the Life Sciences careers evening in January. In 1997, at least 70 3rd and 4th year students indicated their interest in 4th year projects or graduate studies at the Fall Pathology orientation evening. In addition, the Department has a limited budget to invite excellent students to visit the Department from other centres. Together, these initiatives have improved the profile of the Department of Pathology in the Life Sciences programme and recruitment for graduate studies.

OUTREACH:

During the past year, several outreach initiatives involving graduate students and Faculty members in the Department have been developed. Some students as well as some members of the Department have been involved in a Cancer Conference presented to some of the local public schools. This programme is organized by faculty and students in the Departments of Oncology, Biochemistry and Pathology. In addition, some students have been involved as judges for the Frontenac Lennox & Addington Science Fair.

GRADUATE STUDENT PRESENTATIONS:

Graduate students were honoured by invitations to present their research at national/international conferences. These are outlined below:

- | | |
|------------------|--|
| David Hipfner | 88th Annual Meeting of the American Association for Cancer Research. San Diego, CA April 12-16, 1997 |
| Jennifer McVeigh | Thirteenth Annual Meeting on Oncogenes
Frederick, Maryland June 18-21, 1997 |
| Kimberly Wynd | XVth Congress of the International Society on Thrombosis and
Haemostasis. Florence, Italy June 6 - 12, 1997 |
| Carla Cuthbert | XVth Congress of the International Society on Thrombosis and
Haemostasis. Florence, Italy June 6 - 12, 1997 |
| Megan Begbie | XVth Congress of the International Society on Thrombosis and
Haemostasis. Florence, Italy June 6 - 12, 1997 |
| Kelly Wilton | XVth Congress of the International Society on Thrombosis and
Haemostasis. Florence, Italy June 6 - 12, 1997 |
| Angela Keightley | XVth Congress of the International Society on Thrombosis and
Haemostasis. Florence, Italy June 6 - 12, 1997 |
| Yotis Senis | XVth Congress of the International Society on Thrombosis and
Haemostasis. Florence, Italy June 6 - 12, 1997 |
| Jay White | Retinoids '97 Conference, Nice France. September 28-October 1,
1997 |
| Lawrence Martens | American Society of Human Genetics Meeting, Baltimore, MD.
October 28 - November 2, 1997 |
| Lee Fraser | American Society of Human Genetics Meeting, Baltimore, MD.
October 28 - November 2, 1997 |
| | The International Human Genome Meeting. Toronto, ON. March 6-
8, 1997 |

RESEARCH SEMINAR SERIES

The Department of Pathology Research Seminar Series is held every Tuesday during the academic year in Richardson Amphitheatre at 4:00 p.m. Speakers include Graduate Students, Pathology Faculty, and invited speakers from both within and outside of Queen's University. The following seminars were presented by graduate students in 1997:

- | | |
|-----------------------------|---|
| Mr. Jay White | Isolation and Characterization of a Retinoic Acid-inducible, Retinoic Acid Metabolizing Cytochrome P450 |
| Mr. Dennis Kim | The Search for Molecular Targets of Fps/Fes Kinase |
| Mr. Mian Gao
Ms Kim Wynd | Structure and Function of Human Multi-drug Resistance protein, MRP
Adenoviral Receptor Mediated Endocytosis Transgene Delivery into Human and Mouse Hepatocyte Cell Lines: Implications for Gene Therapy |
| Ms Kelly Wilton | Factors Influencing the Recovery of Hemophilia B Leyden Mutations |
| Mr. Jin Gui | Role of HGF Receptor/MET Family Members in Mammary Tumor Progression |
| Ms Sarah Ely | Inflammation, Serum Amyloid A, and Cholesterol Metabolism |
| Ms Carla Cuthbert | Filling in the Gaps of vWF Gene Expression |
| Mr. Yotis Senis | Using Transgenic Mice to Study the Pathophysiological Role of Fps Tyrosine Kinase in Haematopoiesis and Oncogenesis |
| Mr. Chris Davidson | Characterization of the Interaction Between Heparan Sulphate and the Beta-Amyloid Protein (AB) - An Experimental Plan |

COUNCIL OF ONTARIO UNIVERSITIES PERIODIC APPRAISAL

In July 1996, the Appraisals Committee of the Council of Ontario Universities evaluated the Master's and Doctoral programs in the Department of Pathology. Periodic appraisals of the graduate programs are undertaken at seven year intervals by the Ontario Council on Graduate Studies. A detailed brief, outlining all aspects of the Graduate Program in the Department was prepared and submitted to the School of Graduate Studies and Research in May 1996, for final submission to the Council of Ontario Universities. In February 1997, the Department was informed that the Appraisals Committee had approved the MSc/PhD Program in Pathology with an "A" rating. The next accreditation will be in 2003.

GRADUATE COURSES

The following graduate courses were offered in 1997:

Clinical Cytogenetics - Pathology 811

The course content involves both theoretic and practical aspects of chromosome analysis as it pertains to human disease. This course has not been offered in the past due to insufficient enrolment. The Graduate Studies Committee has recommended its discontinuation and removal from the Calendar to Division I (February 1998). The essential aspects of this course have been incorporated into other current courses in the Department.

Cancer Biology - Pathology 823

This course is co-ordinated by Dr. Bruce Elliott. Essential questions in clinical and basic oncology are introduced and discussed. The course is offered in alternate years. In 1996, 18 students were enrolled.

Graduate Pathology for Non-Medical Students - Pathology 824/410

The course co-ordinator is Dr. Robert Kisilevsky. This course provides a general introduction to the pathological processes involved in common human disease. The course is offered annually in the Fall. Four graduate students were enrolled in the Fall term of 1997.

Human Genetics - Pathology 825

The course co-ordinator is Dr. Sherryl Taylor. Molecular mechanisms responsible for human disease are discussed with examples of diagnostic studies. The course is offered in alternate years in the Winter term. In the Winter term of 1996, 11 students were enrolled.

The Molecular Basis of Disease - Pathology 826

The course co-ordinator is Dr. Robert Kisilevsky. This graduate course is offered alternate years and was run for the first time in the Winter term of 1995 with an enrolment of 11. Enrolment in 1997 was 12. The course reviews in detail the pathogenic details of four specific areas of tumour disease.

DEPARTMENT OF PATHOLOGY GRADUATE STUDENTS 1997

Student Name	Program	Start Date	- Supervisor
ABU-ABED, Suzan	MSc	01/97	Dr. Petkovich
ALMQUIST, Kurt	MSc PhD	01/93 09/95	Drs. Cole/Deeley
BEGBIE, Megan	MSc	09/95	Dr. Lillicrap
CUTHBERT, Carla	PhD	09/94	Dr. Lillicrap
DAVIDSON, Chris	PhD	09/97	Dr. Kisilevsky
ELY, Sarah	MSc	09/96	Dr. Kisilevsky
GAO, Mian	MSc	09/95	Dr. Deeley
HIPFNER, David	PhD	09/93	Drs. Cole/Deeley
GUI, Jin	PhD	09/96	Dr. Elliott
IVANCHUK, Stacey	MSc	09/94	Dr. Mulligan
KEIGHTLEY, Angela	MSc	09/93	Dr. Lillicrap
KIM, Dennis	MSc	09/95	Dr. Greer
KLASSEN, Jennifer	MSc	09/94	Dr. Elliott
LI, Chun-yan	MSc	09/96	Dr. Kisilevsky
MARTENS, Lawrence	MSc	01/95	Dr. Kennedy
MATTHEWS, Ben	MSc	09/97	Dr. LeBrun
McVEIGH, Jennifer	MSc	09/94	Dr. Greer
POLLETT, Jonathan	MSc	09/95	Dr. Mueller
SAULNIER, Ronald	PhD	09/92	Dr. Elliott
SENIS, Yotis	MSc	01/94	Dr. Giles
ST. ONGE, Bob	MSc	09/97	Dr. Davey
UDELL, Chris	MSc	05/97	Dr. Davey
WEIGL, Kevin	MSc	09/97	Dr. Cole
WHISKIN, Karen	MSc	01/97	Dr. Mueller
WILTON, Kelly	MSc	09/96	Dr. Lillicrap
WHITE, Jay	MSc	09/93	Dr. Petkovich
WONG, Joyce	MSc	01/93	Dr. Giles
WOOLTORTON, Eric	MSc	09/93	Dr. Mueller
WRIGHT, Scott	MSc	09/95	Drs. Cole/Deeley
WYND, Kim	MSc	09/96	Dr. Lillicrap
YOUNG, Leah	PhD	09/94	Dr. Gerlach

**Graduate Student Photograph
1997-98**

Standing (Left to Right)

Kelly Wilton, Angela Keightley, Sarah Ely, Ben Matthews, Chris Davidson, Dennis Kim, Jin Gui, Chunyan Li, Mian Gao, Chris Udell, Kevin Weigl

Seated (Front)

Yotis Senis, Carla Cuthbert, Suzie Abu-Abed, David Hipfner, Bruce Elliott

Seated (Back)

Bob St. Onge, Karen Whiskin



POSTGRADUATE (Written by Mrs. Jean Guindon)

Dr. Lois Shepherd is the Director of the Postgraduate Education Program in the Department of Pathology and also the Director of General Pathology. Dr. David Hurlbut is the Director of Anatomic Pathology and Dr. Samuel Ludwin is the Director of Neuropathology. The Director of Hematology appointment remains unfilled. Ms. Barbara Saunders is the Administrator of the Postgraduate Education Program in the Department.

Resident Appointments

January 1 - June 30, 1997

Dr. Monique Arquint	PGY-5 (RIV)	General Pathology
Dr. Konrad Chan	PGY-3 (RII)	General Pathology
Dr. Navdeep Gill	PGY-3 (RII)	General Pathology
Dr. Plamen Kossev	PGY-5 (RIV)	Anatomic Pathology
Dr. David Kydd	PGY-4 (RIII)	Neuropathology
Dr. Sanjay Lambore	PGY-5 (RIV)	General Pathology
Dr. Michael Rutherford	PGY-3 (RII)	Anatomic Pathology
Dr. James Safadi **	PGY-2 (RI)	General Pathology
Dr. John Vu	PGY-3 (RII)	General Pathology
Dr. Changgao Yang	PGY-5 (RIV)	General Pathology
Dr. Richard Yu	PGY-4 (RIII)	General Pathology

** Jan - Apr 1997; Suspended from program Apr/97; Withdrew program Jul/97

PGY-1 Appointments (Clinical Internships)

January 1 - June 30, 1997

There are no PGY-1 appointments for this period.

Resident Appointments

July 1 - December 31, 1997

Dr. Konrad Chan	PGY-4 (RIII)	General Pathology
Dr. Navdeep Gill	PGY-4 (RIII)	General Pathology
Dr. Plamen Kossev	PGY-6 (RV)	Anatomic Pathology
Dr. David Kydd	PGY-5 (RIV)	Neuropathology
Dr. Michael Rutherford	PGY-4 (RIII)	Anatomic Pathology
Dr. John Vu **	PGY-4 (RIII)	General Pathology
Dr. Changgao Yang	PGY-5 (RIV)	General Pathology (Jul 1 - Aug 22/97)
Dr. Richard Yu	PGY-5 (RIV)	General Pathology

** Leave of Absence Jul/97 - Jun/98; Withdrew program Oct/97

PGY-1 Appointments (Clinical Internships)

July 1 - December 31, 1997

POSTGRADUATE STUDIES (cont'd...)

Awards

- M. Rutherford** Dr. Robert S.A. Prentice Annual Prize for best presentation by a pathology resident at Queen's University.
- N. Gill** and Dr. Sandip SenGupta shared the first prize award for their poster presentation at the OAP Annual Meeting, "The Changing Role of the Pathologist?"
- M. Arquint** Recipient of the 1st Annual W.E.N. Corbett Prize for residents for Diagnostic Excellence in Clinical Pathology.

Conferences (Pr - presentation paper and Po - poster)


- K. Chan.** Extra-genital malignant mixed mullerian tumour. A case report. CAP Meeting, Vancouver 1997, (Po).
- K. Chan.** Getting the most out of surgical pathology turnaround data: use of laboratory information system result times to analyze intra-laboratory process. OAP Meeting. (Pr)
- N. Gill** and S.K. SenGupta. The Changing Role of the Pathologist. Presented at the 1997 Annual Meeting of the Ontario Association of Pathologists. (Po)
- M. Rutherford.** Expression of Transcription Factor E2A in Human Tissue. Presented at the 1997 Annual Meeting of the Ontario Association of Pathologists. (Pr)

Publications

- Michael N. Rutherford,** Aseem Kumar, Jaharul Haque, Jacques Ghysdael and Bryan Williams. Specific Binding of the ETS-Domain Protein to the Interferon-Stimulated Response Element. Journal of Interferon and Cytokine Research 17:1-10, 1997.

COURTESY OF
KGH ARCHIVES

*RESEARCH PROJECTS AND GRANTS
IN PROGRESS*



RESEARCH PROGRAMS

Research is broadly grouped into five main areas. Amyloid and Alzheimer's Disease, Cancer Research, Hemostasis and Thrombosis, Molecular and Cytogenetics, and Neuropathology Research. Active collaboration exists between members of the Department of Pathology and the Departments of Biochemistry, Immunology, Infection Control, Medicine, Microbiology and Pediatrics. Investigators in the Department thus have enhanced research opportunities by linking their efforts with individuals in other departments and institutes on campus.

Dr. A.H. Boag: Dr. Boag's research projects involve: 1) Expression of Multidrug Resistance Protein in Lung Cancer (with Drs. Cole & Deeley); 2) The Role of Prostatic Inflammation in Benign Prostatic Hyperplasia (with Dr. C. Nickel); 3) Stromal Interactions in Breast Cancer Metastasis: Role of Hepatocyte Growth Factor and Extracellular Matrix (with Dr. B. Elliott); 4) Endogenous Galectin Expression in the Male Urogenital Tract. In collaboration with Dr. H. Ceri (University of Calgary), Dr. J.C. Nickel (Dept. of Urology) and Dr. I. Young (Dept. of Pathology); 5) Human Tumour Tissue Banking Project; 6) Loss of heterozygosity in the Cowden's Gene Region of chromosome 10 in sporadic breast and prostate cancer (with Dr. Lois Mulligan); 7) Mechanisms of Drug Resistance in Prostatic Adenocarcinoma: Expression of Multidrug Resistance-associated Protein, P-Glycoprotein, LRP and Topoisomerase II (with Dr. B. Campling); 8) Expression of Multidrug Resistance-associated Protein in Serous Neoplasms of the Ovary (in collaboration with Dr. Steve Ades (Department of Medicine) and Dr. B. Campling (Cancer Research Group); 9) Outcome Analysis of Resected Non-Small Cell Lung Cancer at Kingston General Hospital, 1988-1997 (with Drs. Sebastien Gilbert and D. Petsikas, Department of Surgery, Kingston General Hospital and Queen's University); 10) Development of a Semi-Quantitative PCR Assay for Assessment of Familial Breast Cancer Risk (with Dr. Sherryl Taylor).

Dr. S.P.C. Cole: Dr. Cole's research projects involve 1) Drug resistance in small cell lung cancer; 2) Cellular and molecular studies of MRP-related multidrug resistance (with Dr. R. Deeley); 3) Monoclonal antibodies specific for extracellular epitopes of MRP (with Dr. R. Deeley); 4) Antisense oligonucleotide-mediated suppression of multidrug resistance in cultured cells overexpressing multidrug resistance-associated protein (MRP) (with R.G. Deeley); 5) Drug resistance conferred by multidrug resistance-associated protein (MRP) (with Dr. R. Deeley); 6) Molecular mechanisms of drug resistance (with Drs. B. Campling and R. Deeley); 7) Investigations of topoisomerase II and drug resistance.

Dr. C.P. Collier: Dr. Collier's research projects involve 1) Bedside glucose monitoring outcome survey (with Drs. R. Houlden, S. Rhymer, K. Gleeson); 2) Myoglobin & Troponin II - multidisciplinary studies (with K. Gleeson, N. Ali, R. Morton, J. Drover, G. Dagnone); 3) Total lipids versus triglycerides as an indicator of malabsorption of intra lipids in neonates (with K.F. Young-Tai, S. Thomsson); 4) Troponin I in angioplasty patients (with A. Lipson N. Ali); 5) Lp(a) evaluation of Hydrasys electrophoresis (with A. Groll); 6) Webpage for clinical biochemistry (with K. Yu); 7) Multivariate analysis of QC from multichannel analyzers (with M. Bramley, M. Griffin, T. Smith); 8) Interaction between serine metabolism and deficiency of vitamin B12 (M. Sabloff, J. Matthews); 9) External quality assessment survey (with R. Yu); 10) Laboratory utilization - focus projects (L. Corcoran).

Dr. R.G. Deeley: Dr. Deeley's research projects involve 1) Effect of estrogen on gene expression in liver; 2) Monoclonal antibodies specific for extracellular epitopes of MRP (with S.P.C. Cole); 3) Molecular and cellular studies of MRP-related multidrug resistance (with S.P.C. Cole); 4) Drug resistance conferred by multidrug resistance associated protein (with S.P.C. Cole); 5) Antisense oligonucleotide-mediated suppression of multidrug resistance in cultured cells overexpressing multidrug resistance-associated protein (MRP) (with S.P.C. Cole); 6) Molecular basis of cisplatin resistance in small cell lung cancer line (with B. Campling, J. Gerlach); 7) Mechanisms in drug resistance (with S. Cole, B. Campling).

Dr. G. Delisle: Dr. Delisle's research projects involve 1) Microbes in Motion-CD-ROM hypermedia program (with L. Tomalty); 2) Biofilm data base collection; 3) Hyperclinic CD-ROM (with L. Tomalty); 3) ASM National collection of microbiological materials (with F. Pfaender); 4) Development of Internet based CME course.

Dr. D. Dexter: Dr. Dexter's research projects involve: 1) Image collection, digitization and data bank archive.

Dr. A.M.V. Duncan: Dr. Duncan's research projects involve 1) Networks of Centres of Excellence - Genetic Diseases Network; 2) Radiation induced chromosome damage; 3) Cat eye syndrome; 4) Canadian Genetic Diseases Network - Innovations for Health Care and Industry; and 5) The Indifferent Gonad - Paradigm Lost.

Dr. B.E. Elliott: Dr. Elliott's research projects involve: 1) Role of an hepatocyte growth factor autocrine loop in growth and metastasis of breast cancer; 2) HGF receptor (Met) and phosphatidylinositol 3-kinase as possible targets for therapeutic intervention of breast cancer metastasis; 3) Regulation of anchorage-independent growth in breast cancer: role of signalling by extracellular matrix & growth factors.

Dr. A. Fletcher: Dr. Fletcher's research projects involve: 1) A novel approach to the diagnosis and treatment of endometriosis; photodynamic therapy.

Dr. S.E. Ford: Dr. Ford's research projects involve 1) Clinical Association of Cardiopilin Antibodies in an Autopsy Population; 2) Study of infectious disease and disease prevention by risk avoidance in prisons; 3) Development and application of longitudinal "treatment adherence" questionnaire for patients treated with proteinase inhibitors for HIV.

Dr. A.R. Giles: Dr. Giles' research projects involve 1) The Regulation of Hemostasis in Health & Disease; 2) The Role of Alpha 1-Proteinase Inhibitor in Regulating Neutrophil Elastase in Experimental and Clinical Disseminated Intravascular Coagulation; 3) Study of Factor X Variants in Hemophilic and Normal Dogs; 4) Preclinical Animal Studies; 5) Basic and Applied Studies of the Molecular Biology of F.VIII Trafficking to Platelet 2-Granules; 6) The Regulation of Gene Expression and Product Availability in Shear Stress and Thrombin Stimulated Endothelium in Vivo.

Dr. P.A. Greer: Dr. Greer's research projects involve: 1) A transgenic analysis of *fps/fes* proto-oncogene function; 2) Regulation of the *fps/fes* proto-oncogene; 3) Molecular basis of acute promyelocytic leukemia.

Dr. K. Harrison: Dr. Harrison's research projects involve: 1) Genome analysis of various rhabdomyosarcoma subtypes using comparative genomic hybridization; 2) Uniparental disomy in Robertsonian translocation carriers.

Dr. D. Hurlbut: Dr. Hurlbut's research projects involve: 1) Apoptosis in inflammatory bowel disease.

Dr. R. Kisilevsky: Dr. Kisilevsky's research projects involve: 1) Amyloidogenesis: an analysis of the causative factors in an experimental murine model; 2) An approach to the development of a treatment for amyloids and Alzheimer's disease.

Dr. D. LeBrun: Dr. LeBrun's research projects involve: 1) Subcellular localization of the E2A-PBX1 leukemogenic transcription factor; 2) The E2A-PBX1 chimeric transcription factor in leukemia; 3) Biological consequences of E2A-PBX1 expression.

Dr. D. Lillicrap: Dr. Lillicrap's research projects involve: 1) Characterization of mechanisms regulating the developmental expression of coagulation factor IX; 2) The control of von Willebrand factor expression; 3) Post-transcriptional regulation of factor VIII expression; 4) Transcriptional regulation of the factor VIII gene; 5) Flow effects on endothelial cell expression of von Willebrand factor.

Dr. S.K. Ludwin: Dr. Ludwin's research projects involve: 1) Demyelination, remyelination and oligodendrocyte behaviour in vivo and in organotypic cultures of the central nervous system; and 2) Collaborative work on Alzheimer's Disease (with Dr. R. Kisilevsky).

Dr. P.N. Manley: Dr. Manley's research project involves 1) Contract - Collection, verification and dissemination of tissue sections of study material; 2) Letter of intent - Improving health outcomes through the laboratory (Canadian Health Services Research Foundation).

Dr. D. Maurice: Dr. Maurice's research projects involve: 1) Cyclical nucleotide phosphodiesterases in arteries; 2) The regulation of gene expression and product availability in shear stress and thrombin stimulated endothelium in vivo; 3) Effects in nitrovasodilators, NO and CO on blood vessel function; 4) Mechanisms of erectile dysfunction.

Dr. J. Rossiter: Dr. Rossiter's research projects involve: 1) Molecular mechanisms of axotomy-induced apoptosis of rat facial motoneurons; 2) Motoneuron rescue with HSU encoding Bcl-2; 3) The expression of the GDNF/RET ligand complexes following peripheral nerve anatomy.

Dr. C. Rowlands: Dr. Rowland's research projects involve: 1) Cytology of granulocytic sarcoma in effusions; 2) Response of psoriatic lesions to topical "skincap".

Dr. S. SenGupta: Dr. SenGupta's research projects involve: 1) Histopathologic and clinical differences between short and long term survivors of breast cancer; 2) Study of breast cancer and the environment (with K. Aronsen); 3) Assessment of NSAIDS in osteoarthritis using growth-factor mediated matrix formation by chondrocytes (with T. Anastassiades and R. Chopra); 4) Histological characteristics of wrist soft tissues in rheumatoid and non-rheumatoid patients (with C. Small and D. Pichora); 5) Investigation of the biomechanical environment for lumbar fusion (with D. Yen); 6) Study of survival outcomes of breast carcinoma patients treated at KRCC, based on histopathologic and clinical prognostic factors (with D. Ginsburg).

Dr. Lois Shepherd: Dr. Shepherd's research projects involve: 1) Canadian Study Chair NCIC CTG Co. 9 - A phase III evaluation of high dose levamisole plus 5-fluorouracil and leucovorin as surgical adjuvant therapy for high risk colon cancer; 2) A multicentre randomized study of dose intensive chemotherapy as primary treatment in a multimodality approach for locally advanced/inflammatory breast cancer (MA10); 3) A double-blinded randomized trial of tamoxifen versus placebo in premenopausal, node positive and node negative women who have completed adjuvant chemotherapy (MA12); 4) A randomized trial of antiestrogen therapy versus combined antiestrogen and octreotide LAR therapy in the adjuvant treatment of post-menopausal breast cancer (MA14); 5) A phase I/II study of docetaxel and epirubicin as first line therapy for metastatic breast cancer (MA15); 6) A randomized comparative trial of high dose chemotherapy and autologous stem cell support vs standard therapy following response to anthracycline or taxane chemotherapy in women with metastatic breast cancer (MA16); 7) A phase III randomized double blind study of vorozole versus placebo in women with primary breast cancer completing five or more years of adjuvant tamoxifen (MA17); 8) Chemotherapy with 5-FU and 1-leucovorin following potentially curative resection of liver or lung metastasis from colorectal cancer (CO7); 9) Evaluation of 5-FU by bolus injection versus 5-FU by prolonged venous infusion versus 5-FU by bolus injection plus leucovorin and levamisole prior to and following combined prolonged venous infusion 5-FU plus pelvic XRT in patients with rectal cancer (SWOG 9304) (CO11); 10) Phase III prospective randomized trial comparing laparoscopic assisted colectomy versus open colectomy for colon cancer (INT 0146) (CO12); 11) Radiotherapy or radiotherapy plus ABVD versus ABVD alone in early stage Hodgkin's disease (HD6) 12) A phase 1/11 study of chemotherapy intensification for patients with poor prognosis advanced stage aggressive histology lymphoma: VACOP-B plus etoposide and cyclophosphamide with RhuGM-CSF (VACOP-B/EC/CSF) (LY4). Coinvestigator: 13) EBV and Intermediate Risk Lymphoma; 14) A Tumour, Tissue, and Clinical Data Bank for Breast Cancer Patients Participating in NCIC CTG Clinical Trials; 15) Prognostic Factor Panel to Predict Preferred Therapy for Node Positive Postmenopausal Breast Cancer Patients (CAF vs Tamoxifen). Biologics Companion to SWOG 9941.

Dr. S.A.M. Taylor: Dr. Taylor's research project involves: 1) Development of a molecular genetics testing program for inherited breast and ovarian cancer; 2) Genetic analysis of the BRCA1 gene in familial breast and ovarian cancer; 3) Ontario registry for studies of familial breast cancer; 4) Ontario registry for studies of colorectal cancer; 5) Genetic determinants of salt-sensitive hypertension; 6) A semi-quantitative PCR based assay for the assessment of familial breast cancer risk; 7) Molecular and cytogenetic delineation of Aicardi Syndrome.

Dr. L. Tomalty: Dr. Tomalty's research projects involve: 1) Hyperclinic: Interactive case studies

in microbiology - development of interactive CD-ROM program in medical microbiology (with G. Delisle); 2) Development of Internet based CME course (with G. Delisle); 3) Epidemiology of candida colonization in NICU setting (with Dr. Young-Tai).

Dr. D. Zoutman: Dr. Zoutman's research projects involve: 1) National Multiresistant *Staphylococcus aureus* (MRSA) Surveillance Project; 2) Hospital Utilization Improvement Trial of Surgical Prophylactic Antibiotics phase 3, analytical component; 3) Interactions between pyocyanin and nitric oxide; 4) National surveillance of nosocomial surgical wound infections - Project Leader of Canadian Hospital Epidemiology Committee; 5) Phase 2 Randomized Double Blind Placebo Controlled Trial of GG167 in the Treatment of Influenza Infections; 6) Phase 3 Randomized Double Blind Placebo Controlled Trial of GG167 in the Treatment of Influenza Infections; 7) Quantitative Analysis of Exposures to Blood Born Pathogens By Corrections Canada Staff in 5 Maximum Security Institutions; 8) National Survey of TB Patient Education Strategies; 9) National Study of Epidemiology of Central Intravenous Catheter Related Infections; 10) National Study of Incidence of *Clostridium difficile* infections in Canadian Hospitals; 11) Development & testing of a new antimicrobial drug of which I am an inventor (with Drs. Nakatsu, Brien, Marks & Vukomanovic); 12) Design and creation of patient education video and interactive CD ROM on "Adherence to Tuberculosis Medications" (with Dr. E. Costello, School of Nursing).

1997 RESEARCH PROJECTS AND GRANTS

NAME	AGENCY	AMOUNT	TITLE OF RESEARCH PROJECT
Dr. S. Cole	NCIC	\$32,500	Drug Resistance in Small Cell Lung Cancer
Dr. S. Cole & Dr. R. Deeley	ISIS	\$50,000	Antisense Oligonucleotide-mediated Suppression of MRP Expression
Dr. S. Cole & Dr. R. Deeley	Centocor	\$50,000	Monoclonal Antibodies Against Extracellular Epitopes of MRP
Dr. S. Cole & Dr. R. Deeley	MRC	\$115,000	Cellular and Molecular Studies of Drug Resistance Mediated by MRP
Dr. B. Campling, S. Cole and R. Deeley	NCIC	\$307,113	Molecular mechanisms of Drug Resistance
Dr. C. Collier	Pathology Clinical Trust Fund	\$2,850	Cost Effective Triage for Chest Pain by Analysis of Myoglobin and Troponin I
Dr. R. G. Deeley	Medical Research Council	\$92,936	Effect of estrogen on gene expression in liver
Drs. R.G. Deeley & S. Cole	Medical Research Council	\$39,266	Molecular basis of drug resistance in a lung carcinoma cell line
Drs. R.G. Deeley & S. Cole	National Cancer Institute	\$113,000	Drug resistance conferred by multidrug resistance associated protein (MRP)
Dr. R. Deeley & Dr. S. Cole	ISIS	\$50,000 US	Antisense Oligonucleotide-mediated Suppression of MRP Expression
Dr. R. Deeley & Dr. S. Cole	Centocor	\$50,000 US	Monoclonal Antibodies Against Extracellular Epitopes of MRP
Drs. B. Campling, J. Gerlach, R. Deeley	MRC	\$39,266	Molecular Basis of Cisplatin Resistance in Small Cell Lung Cancer Line.
Dr. G. Delisle & Dr. L. Tomalty	Wm. C. Brown Publishers	\$105,000	CDROM Production of "Microbles in Motion". Textbook on Microbiology
Drs. G. Delisle, L. Tomalty	Wm. C. Brown Publishers	\$\$50,000US	Hyperclinic CD ROM
Drs. G. Delisle, F. Pfaender	National Science Foundation	\$155,000US	ASM National Collection of Microbiological Materials
Dr. G. Delisle	Queen's SWEP	\$3,500	SWEP Student Summer Assistant

Dr. G. Delisle	Waxman Foundation	\$150,000US	CD ROM production ASM - Biofilms - American Society for Microbiology
Dr. A. Duncan	Pathology Clinical Trust Fund	\$8,000	
Dr. B. Elliott	Canadian Breast Cancer Foundation	\$25,000	HGF Receptor (Met) and Phosphatidylinositol 3-kinase as Possible Targets for Therapeutic Intervention in Breast Cancer Metastasis
Dr. B. Elliott	US Army Breast Cancer Research Initiative	\$ 78,982 US	Role of an hepatocyte growth factor autocrine loop in growth and metastasis of breast cancer
Dr. B. Elliott	MRC Maint. Grant	\$25,000	Maintenance grant for flow cytometer and confocal microscope facility
Dr. B. Elliott	OCTRF	\$20,000	PDF Stipend
Drs. A. Fletcher, R.L. Reid, D.A. VanVugt, J.C. Kennedy	MRC	\$69,798	A Novel Approach to the Diagnosis and Treatment of Endometriosis: Photodynamic Therapy
Dr. A. Giles	MRC	\$103,215	The regulation of hemostasis in Health & Disease
Dr. A. Giles	Bayer Corp.	\$75,000	Evaluation of Modified recombinant F.VIII
Dr. A. Giles	HSFO	\$75,405	The regulation of gene expression and product availability in shear stress and thrombin-stimulate endothelium in vivo
Dr. A. Giles	Bayer/CRS	\$96,600	Role of alpha1-proteinase inhibitor in regulating neutrophil elastase in experimental and clinical disseminated intravascular coagulation
Dr. A. Giles	GTI	\$37,000US	
Dr. A. Giles	H&S Foundation	\$53,250	
Dr. P. Greer	MRC	\$79,000	Regualtion of the fps/fes protooncogene
Dr. P. Greer	NCI	\$79,000	A transgenic analysis of fps/fex protooncogene
Dr. P. Greer	MRC	\$49,780	Targets of the PML/RAR α oncogene in acute promyelocytic leukemia: The molecular basis of leukemogenesis

Dr. P. Greer	OCTRF	\$20,000	
Dr. K. Harrison	Queen's University	\$30,000	Startup Funds
Dr. R. Kisilevsky	NEUROCHEM Inc.	\$160,000	An approach to the development of a treatment for amyloids and Alzheimer's disease
Dr. R. Kisilevsky	NEUROCHEM Inc.	\$330,000	An approach to the development of a treatment for amyloids and Alzheimer's disease
Dr. R. Kisilevsky	MRC	\$97,000	Amyloidogenesis: an analysis of the causative factors in an experimental murine model
Dr. D. LeBrun	NCIC	\$91,573	Biological consequence of E2A-PBX1 expression
Dr. D. LeBrun	Hosp. For Sick Children	\$63,797	The E2A-PBX1 Chimeric transcription factor in Leukemia
Drs. D. Lillicrap	Canadian Hemophilia Society	\$61,000	Post-transcriptional regulation of FVIII expression
Dr. D. Lillicrap	Heart & Stroke Foundation	\$ 59,212	The control of von Willebrand factor expression
Dr. D. Lillicrap	Heart & Stroke Foundation	\$66,662	Transcriptional regulation of the factor VIII gene
Dr. D. Lillicrap	Pathology Clinical Trust Fund	\$5,000	Flow effects on endothelial cell expression of von Willebrand factor
Dr. D. Lillicrap	MRC	\$100,926	Characterization of mechanisms regulating the developmental expression of coagulation factor IX
Dr. D. Lillicrap	H&S	\$53,500	Career Investigator Award
Dr. S.K. Ludwin	MRC	\$ 66,187	Demyelination, remyelination and oligodendrocyte behaviour in vivo and in organotypic cultures of the central nervous system
Dr. P. Manley & Dr. J. Pater	NCIC	\$42,500	Contract: Collection, verification and dissemination of tissue sections of study material

Dr. D. Maurice	HSFO	\$71,987	Cyclic nucleotide phosphodiesterases in arteries
Dr. D. Maurice, Dr. A. Giles, Dr. M. Richardson	HSFO	\$74,855	The regulation of gene expression and product availability in shear stress and thrombin stimulated endothelium in vivo
Dr. D. Maurice, Drs. Adams, Heaton	Kidney Foundation	\$40,000	Mechanisms of erectile dysfunction
Dr. D. Maurice	Pharmaceutical Mfg.	\$31,536	
Dr. M. Richardson	HSFO	\$70,612	Endothelial Injury and Atherosclerosis
Dr. J. Rossiter	NCE Neuroscience Network	\$20,000	Motoneuron rescue with HSU encoding Bcl-2
Dr. J.P. Rossiter	ALS Society of Canada	\$35,000	Molecular Mechanisms of Axotomy-Induced Apoptosis of Rat Facial Motoneurons
Dr. J. Rossiter	Botterell Foundation	\$39,500	The expression of the GDNF/RET ligand complexes following peripheral nerve axotomy
Drs. L. Shepherd, E. Eisenhower, K. James, B. Zee, J. Myles & J. Pater	NCIC	\$2,635,581	Clinical Trials Group
Drs. L. Shepherd, K. Pritchard, P. Watson, M. Pollak	NCIC	\$47,399	Clinical Trials - A tumour, tissue and clinical data bank for breast cancer patients
Dr. S. Taylor	Pathology Clinical Trust	\$3,759	
Drs. S. Taylor, D. Pross, C. Forster, D. Lillicrap, R. Deeley, L. Mulligan, M. Khalifa, E. Sterns	OCTRF	\$45,878	Genetic analysis of the BRCA1 gene in familial breast and ovarian cancer
Dr. S. Taylor, et al	NIH	\$20,000	Genetic analysis of the BRCA1 gene in familial breast and ovarian cancer
Dr. S. Taylor	OCTRF	\$36,700	
Dr. S. Taylor	KRCC	\$12,000	
Dr. S. Taylor	OAML	\$11,000	A semi-quantitative PCR based assay for the assessment of familial breast cancer risk

Dr. S. Taylor	PSI	\$62,000	Molecular and cytogenetic delineation of Aicardi Syndrome
Dr. L. Tomalty & Dr. G. Delisle	McGraw Hill Comp.	\$70,000	Interactive case studies in Microbiology - development of interactive CDROM
Drs. L. Tomalty & D. Delisle	Queen's University	\$3,400	SWEP Student
Drs. L. Tomalty & Y. Tai	Pediatrics, KGH	\$2,500	Epidemiology of Candida colonization in NICU setting
Dr. D. Zoutman	Glaxo Wellcome Incorporated	\$35,000	Randomized Clinical Trial of GG167 in Treatment & Prevention of Influenza A & B Infections
Dr. D. Zoutman	Canadian Lung Association	\$17,254	Design and creation of Patient Education Video and Interactive CD ROM
Drs. D. Zoutman & E. Costello	Ontario Lung Association	\$17,104	Design and creation of Patient Education Video and Interactive CD ROM
Dr. D. Zoutman	Lab. Center for Disease Control	\$10,000	National study of Epidemiology of Central Intravenous Catheter Related Infections
Dr. D. Zoutman, Dr. E. Costello	Ontario Lung Association	\$ 2,916	National Survey of TB patient education strategies

COURTESY OF
KGH ARCHIVES

DEPARTMENT OF PATHOLOGY
VISITING LECTURERS
1997

VISITING LECTURERS
1997

"How to Replicate an End: New Players for Telomere Maintenance in Yeast"

Dr. Raymund Wellinger, University of Sherbrooke, January 14, 1997

"Integrin Signalling in Carcinoma Progression"

Dr. Arthur Mercurio, Laboratory of Cancer Biology, Deaconess Hospital, Harvard Medical School, January 15, 1997

"The P75 Neurotrophin Receptor: A Molecular Double Agent"

Dr. Rick Riopelle, Dept. of Medicine, Queen's University, February 25, 1997

"Inactivation of the Retinoblastoma-related Proteins by Simian Virus"

Dr. James de Caprio, Dana-Farber Cancer Institute, Harvard University 40 Large Tumour Antigen, March 11, 1997

"Microdissecting the Invasive Phenotype in Human Breast Cancer"

Dr. Peter Watson, Department of Pathology, University of Manitoba, March 18, 1997

"Studies of the Structural Basis for CFTR Chloride Channel Activity"

Dr. Christine Bear, University of Toronto, April 1, 1997

"Integrins and How Cancer Cells Metastasize"

Dr. Vince Morris, Professor, Dept. of Microbiology & Immunology, University of Western Ontario, May 6, 1997

"The Role of the Adventitia in Arterial Repair"

Dr. Ed O'Brien, Assistant Professor, University of Ottawa, Heart Institute, May 20, 1997

"Coagulation Receptor-Protease Systems: Relevance to Multiple Biological Processes"

Dr. Ed Conway, Department of Medicine, Division of Hematology/Oncology, University of Toronto, September 10, 1997

"Molecular Analysis of Spinal Muscular Atrophy; A Role for Neuronal Apoptosis?"

Dr. Alex MacKenzie, Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, October 14, 1997

"Mechanisms of Hypertension Following Blockade of Nitric Oxide Production"

Dr. Michael Adams, October 28, 1997

"Fetal Alcohol Syndrome: Alcohol Neurobehavioural Teratogenesis Involving the Hippocampus of the Developing Brain"

Dr. James Brien, Dept. of Pharmacology and Toxicology, Queen's University, November 4, 1997

"Inherited Disorders of Platelet Alpha-Granules"

Dr. Catherine Hayward, Departments of Pathology & Medicine, McMaster University, November 21, 1997

"Genetic Alterations in Breast Cancer: Importance in Node-negative Disease"

Dr. Irene Andrulis, Professor of Molecular & Medical Genetics, Univ. of Toronto, Toronto, Ontario, November 25, 1997

"Understanding Myc-dependent Repression of Gene Transcription and Identifying a Tumour-specific Inducer of Apoptosis"

Dr. Linda Penn, Senior Scientist & Associate Professor, Ontario Cancer Institute/University of Toronto, December 3, 1997

"Genetic Control of Vascular Hypertrophy in Experimental Hypertension"

Dr. Stephen Pang, Professor and Head, Dept. of Anatomy & Cell Biology, Queen's University

"Protein Kinases that Regulate Myosin I and Myosin II Activity"

Dr. Graham Cote, Associate Professor, Department of Biochemistry, Queen's University

"Expression of E2A in Human Tissues"

Dr. Michael Rutherford, Resident II, Kingston General Hospital

"Role of the Uterine Microenvironment in the Regulation of Placental Trophoblast Invasion"

Dr. Charles Graham, Assistant Professor, Depts. Anatomy & Cell Biology, Queen's University

**SENIOR STAFF
DEPARTMENT OF PATHOLOGY
AND QUEEN'S UNIVERSITY
LECTURES**

**SENIOR STAFF
DEPARTMENT OF PATHOLOGY
AND QUEEN'S UNIVERSITY
LECTURES**

Dr. S. Cole, Department of Chemistry, Queen's University, February, 1997.

"Drug Resistance in Cancer: From Bench to Bedside and Back Again"

Dr. S. Cole in conjunction with Drs. B. Campling and R. Deeley, presentation to MRC Council

Dr. R. Deeley, Department of Pharmacology and Toxicology, March, 1997 and Department of Biochemistry, March, 1997.

"Of Starch and Silk: Amyloid and Alzheimer's Disease"

Dr. R. Kisilevsky, Prize for Excellence in Research, Queen's University, February, 1997.

"You do not own your own genes"

Dr. D. Lillicrap, First Annual A.A. Travill Debate, Queen's University, Etherington Hall, Auditorium September 18, 1997.

"From Microscopy to Therapy: Pathology and the Study of Amyloidosis"

Dr. I. Young, Resident Research Day, Department of Pathology, Queen's University.

"Clostridium Difficile"

Dr. D. Zoutman, Department of Medicine, Medical Mortality Conference, Queen's University, April, 1997.

"Diagnosis of Infectious Diseases"

Dr. D. Zoutman, Department of Medicine, Grand Rounds, Queen's University, July, 1997.

"Malaria"

Dr. D. Zoutman, Department of Medicine, Medical Mortality Conference, October, 1997.

**SENIOR STAFF
DEPARTMENT OF PATHOLOGY**

**INVITED LECTURERS
OUTSIDE OF KINGSTON**

**INVITED LECTURERS OUTSIDE OF KINGSTON
SENIOR STAFF
DEPARTMENT OF PATHOLOGY**

Dr. S.P.C. Cole 1) Ontario Cancer Institute, Princess Margaret Hospital, Toronto, January 1997; 2) Hollings Cancer Center, Charleston, SC, USA, January 1997; 3) 2nd Annual John Doull Toxicology Symposium, Kansas City Medical Center, KS, May 1997; 4) Symposium on Dose Intensification and Drug Resistance in Lung Cancer, 8th World Lung Cancer Conference, Dublin, Ireland, August, 1997; 5) Symposium on Lung Cancer - New Aspects, University of Vienna Medical School, Vienna, Austria, September 1997.

Dr. R. Deeley 1) "From Multidrug Resistance to Genetic Disease", FEBS Advanced Lecture Course, Gosau, Austria, February, 1997; 2) "Mechanisms of Drug Transport", American Association for Cancer Research Annual Meeting, San Diego, April, 1997; 3) "Structure and Function Studies of the Multidrug Resistance Protein, MRP", 6th European ISSX Meeting, Goteborg, Sweden, July, 1997; 4) Department of Physiology, McGill University, September, 1997; 5) Department of Physiology and Biophysics, University of Iowa, November, 1997.

Dr. G. Delisle 1) "Infectious Disease and the Use of Multimedia Tools", Toronto General Hospital, February, 1997; 2) "The Biofilm Collection and Use of Multimedia in Education", ASM, Fort, Lauderdale, Florida, May, 1997; 3) "Laboratory Standards of Practice for Genital Infections", Canadian Association of Clinical Microbiology and Infectious Disease, St. Johns, NFLD, November, 1997; 4) "Infectious Disease and the Internet", Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, September, 1997; 5) "The ASM Biofilm Collection and Innovative Classroom Materials", National Association of Biology Teachers, Minneapolis, MN, USA, October, 1997; 6) "Hyperclinic: Diagnostic Case Studies in Microbiology", American Society Microbiology, Miami, Florida, May, 1997; 7) "The ASM Biofilm Collection and Use of Multimedia in Education", Undergraduate Conference, ASM, Fort Lauderdale, Florida, May, 1997; 8) "Multimedia in the Classroom: Lesson Learned", International Association of Advances in Computers in Education, Calgary, Alberta, June 1997.

Dr. B. Elliott 1) "Hepatocyte Growth Factor in Survival, Growth and Metastasis of Breast Carcinomas: A Potential Target for Therapeutic Intervention?", World Conference on Breast Cancer, Kingston, July, 1997; 2) "Localization of Platelet-Derived Growth Factor B-Receptor, Hepatocyte Growth Factor (HGF), and HGF Receptor/Met in Nonmalignant Human Mammary Tissue and in Breast Cancer", DOD Era of Hope Meeting, Washington, DC, USA, November, 1997.

Dr. P. Greer 1) BioChem Therapeutic Inc., Montreal, Quebec; 2) Loeb Research Institute, University of Ottawa; 3) Centre de Recherche Louis-Charles Simard, University of Quebec; 4) The Institute for Molecular Biology and Biotechnology, McMaster University.

Dr. R. Kisilevsky 1) "Pathobiology of Cell Injury and Cell Death", Experimental Biology '97, New Orleans, LA, USA, April 1997; 2) "Animal Models of Amyloid Aggregation and Deposition", IVth International Conference on Progress in Alzheimer's and Parkinson's Diseases, Eilat, Israel May 1997; 3) "A β Amyloid as a Target for Anti-Alzheimer Therapy", Yamanouchi Pharmaceutical Co.,

Ltd., Tsukuba, Japan, June 1997; 4) "Amyloidogenic Protein: Common Element Interaction as A Target for Anti-Amyloid Therapy", Washington D.C. USA, June 1997; 5) Workshop on: "Proteoglycans in the Developing, Regenerating, and Aging Nervous System Proteoglycans and Amyloidogenesis", Boston, MA, USA, July 1997; 6) "Amyloid and Alzheimer's Disease", Zhejiang Medical University, Hangzhou, Zhejiang, PRC, October, 1997; 7) "Serum Amyloid A and Cholesterol Transport in Inflammation", Peking Union Medical College, Beijing, PRC, October 1997; 8) "A β Amyloid as a Target for Anti-Alzheimer Therapy", Shanghai Medical School Shanghai, People's Republic of China, October 1997; 9) "A β Amyloid as a Target for Anti-Alzheimer Therapy", Chinese Society for Neuroscience, 2nd Congress, Xi'an, People's Republic of China, October 1997; 10) "Anti-Amyloid Small Molecules", Stockholm, Sweden, November 1997; 11) "Amyloid: A Rare Entity Whose Time has Come", Louisiana State University School of Medicine, Shreveport, LA, November 1997.

Dr. D. Lillicrap 1) "Hemophilia: from basic science to molecular diagnosis and genetic therapy", Molecular Medicine Graduate Course Lecture, University of Toronto, January, 1997; 2) "The genetics of von Willebrand disease", Hamilton and Regional Branch of Hemophilia Ontario, Hamilton, ON, February, 1997; 3) "Evolution of hemophilia management through the application of molecular science", First Annual Symposium on Advances in Laboratory Medicine, Hospital for Sick Children, Toronto, June 1997; 4) "Molecular diagnosis in hemostasis", Annual Congress of the Canadian Society of Laboratory Technologists, Charlottetown, PEI, June, 1997; 5) "New therapies for hemophilia", Annual Congress of the Canadian Society of Laboratory Technologists, Charlottetown, PEI, June, 1997; 6) "Gene therapy and hemophilia", Hemophilia Ontario, Ottawa, Ontario, September, 1997; 7) "The in vivo study of gene therapy for hemophilia", Annual Meeting of Hemophilia Clinic Directors of Japan, Fukuoka, Japan October, 1997; 8) "The impact of molecular science on hemophilia A", Nara Medical College, Japan, October, 1997; 9) "Getting blood to clot in 1997", National Red Cross, Ottawa, ON, November 5, 1997.

Dr. S.K. Ludwin 1) Myelin Project Meeting, New York City, USA, March 1997; 2) "Surgical Pathology in the Nervous System" for US-Can. Academy of Pathology, Orlando, Florida, March, 1997; 3) "Pathological Reactions of the Oligodendrocyte", II Congress of the Society of Neuroscience of Africa, April 1997; 4) "Oligodendrocyte Response to Injury", XIIIth International Congress of Neuropathology, Perth, Australia, September, 1997; 5) "Pathological Reactions of the Oligodendrocyte", Annual Meeting of the Association pour la Recherche sur La Sclerose en Plaques, Paris, France, December, 1997.

Dr. P. Manley 1) KPMG, January, 1997; 2) "Academic Issues in the Re-engineered Laboratory: What's Next?", Ottawa, February, 1997; 3) "Reforming Laboratory Services; New Strategies and Directions", Toronto, October, 1997; 4) "Towards Better Patient Outcomes", Bayer Healthcare, Toronto, December, 1997.

Dr. D.H. Maurice 1) "cAMP-Mediated Inhibition of Vascular Smooth Muscle Cell Migration: Role of cAMP-Phosphodiesterases", Washington, DC, December, 1997; 2) "Regulation of cAMP Phosphodiesterase 4 (PDE4) in Rat Aortic Smooth Muscle Cells: role of cAMP", Washington, DC, December 1997; 3) "Cloning of an Atrial cDNA Sequence for Rat von Willebrand Factor (vWF)", Florence, Italy, June 1997.

Dr. S. SenGupta 1) "Emerging Pathogens, Part I", Prince Edward County Memorial Hospital, Picton, April, 1997; 2) "Emerging Pathogens, Part II", Prince Edward County Memorial Hospital, Picton, July, 1997; 3) "Diagnosis and Prognosis of Breast Cancer", Prince Edward County Memorial Hospital, Picton, October, 1997; 4) "Emerging Pathogens", Ongwanada Resource Centre, Kingston, October, 1997; 5) "Update on Laboratory Services Restructuring in Ontario", Central East II Pathologists Group, October, 1997.

Dr. L. Tomalty 1) "Use of Technology to Teach Microbiology", 4th Undergraduate Education Teaching Forum, Fort Lauderdale, Florida, 1997.

Dr. D. Zoutman 1) "Cost Effectiveness of Infection Control", Community and Hospital Infection Control Association-Eastern Ontario Chapter, March, 1997; 2) "Infection Control - Where's the Beef?", Ontario Hospital Association Annual Meeting, Toronto, March, 1997; 3) "Antibiotic Resistant Bacteria", OAP Annual Meeting, Picton, Ontario, June, 1997.

COURTESY OF
KGGH ARCHIVES

SENIOR STAFF COMMITTEES

SENIOR STAFF COMMITTEES

Dr. S. Boag: Director, Histopathology Lab, KGH; Coordinator, Quality Assurance for Anatomic Pathology, KGH; Member, Laboratory Information System Prioritization Group, KGH; Member, Laboratory Information System Specification Group, KGH; Member, Kingston Regional Cancer Centre Lung Site Group; Member, Anatomic Pathology Renovation Committee, Dept. of Pathology, KGH.

Dr. S. Cole: Member, Committee on Policy for Research Grants, Contracts and Consulting Activities; Member, Search Committee, Head of Community Health & Epidemiology; Member, Search Committee, Bader Chair in Organic Chemistry; Member Research Advisory Committee (Oncology); Councillor, Pharmacological Society of Canada; Member, Awards Committee, Cain Subcommittee, AACR; Member, Sustaining Membership Committee, AACR.

Dr. C. Collier: Coordinator, Medical Laboratory Technologist Training Program; Coordinator, Journal Club; Coordinator, Clinical Chemistry Review Sessions; Member, Postgraduate Education Committee; Member, Faculty of Medicine TIPS; Member, Faculty of Medicine Admissions Committee; Instructional Development Center, "Teacher/Scholar Network" Group; Member, Queen's Alumni Teaching Awards Committee; Member, CSCC; Member, AACC, Fellow, CACB, Member, ACB; Member, International Association of Therapeutic Drug Monitoring and Clinical Toxicology; Member, CLMA.

Dr. R. Deeley: Chair, Research Advisory Committee, KRCC; Member, Research Executive Committee, OCTRF; Member, Research Advisory Committee, OCTRF.; Member, Genetic Predisposition to Cancer Management Committee, OCTRF.

Dr. G.J. Delisle: Member, Combined Infection Control Committee KGH/HDH/St. Mary's of the Lake Hospital; Clinical Director, Combined Clinical Microbiology Labs, KGH/HDH; Consultant, Medical Microbiology as Applied to Laboratory Services, KGH/HDH; UMEC Coordinator, Phase I (Micro); Member, Infection Control Committee, HDH; Member, Pharmacy and Therapeutics Committee, HDH; Member, Antimicrobial Use Committee, KGH/HDH; Chair, Distance Education Committee, American Society of Microbiology.

Dr. D. Dexter: Member, HDH/KGH Joint Management Advisory Committee; Member, HDH/KGH Laboratory Computer Interface Committee; Member, CLEO Management Group; Member, Postgraduate Education Committee; Member, MD Finance Committee; Member, Laboratory Consolidation Consultation Committee; Member, HDH/KGH Consolidated Laboratory Services Working Group; Member, Subcommittee for Core, Rapid Response, and Specialty Laboratories; Member, Advisory Committee at AP Consolidation; Member, Hematology Division Committee; Member, Phase I Curriculum Design Committee; Member, Laboratory Services Task Force of the Health Care Network of South Eastern Ontario; Member, General Pathology Residency Programme Committee; Member, Anatomic Pathology Residency Programme Committee; Member, Ad Hoc Committee on Consent for Transfusions; Member, Information Management Team; Member, Pre-Operative Assessment Clinic Committee; Member, Hospital and Patient Services Committee;

Member, Comprehensive Planning Committee of the Board; Founding Member of the Special Resources Committee - Le Royers Patrons; Past Chair, Medical Advisory Committee; Past Chair, Medical Advisory Committee Executive; Chairman, Infection Control Committee; Member, Out Patient Committee; Member, Medical Laboratory Technology Advisory Committee, St. Lawrence College.

Dr. A.M.V. Duncan: Director, Cytogenetics; Senator, University Senate; Ex-officio Member of Faculty Council; Member, Ban Righ Board, Member, Senate Nominations Committee; Faculty rep., Senate Committee on Honorary Degrees; member, Headship of Paediatrics Search Committee; Member, University Grievance Board; Member, Advisory Committee of the Queen's Writing Centre; Member, University Radiation Committee; Member, Task Force on Operations Review; Member, Honorary Degrees Nominating Committee; Member, Hannah Adjunct Search Committee; Member, Promotion/Appointment/Reappointment Committee; Member, Research Advisory Committee; Member, HDH Pathologist Search Committee; Secretary, CCMG; Member, Examination Committee CCMG; Member, Accreditation of Centres Committee CCMG; Member, Education Committee CCMG; Secretary, Genetics Society of Canada; and Member Genetics Cell Culture Committee for the Lab Proficiency Testing Program; Ex-officio Member of Faculty Council; Member Ban Righ Board; Member Senate Nominations Committee; Member, Advisory Committee of the Queen's Writing Centre; Member, Principal's Task Force; Member, Pediatrics Head Search Committee; Member Grievance Board; Member, Honorary Degrees Nominating Committee; Chair, Equity Issues Committee; Member, Pathology Lab Management Committee; Member, Capital Equipment Committee; Member, Research Advisory Committee, Member, Strategic Planning Committee; Ad Hoc Member, Pediatrics Promotions and Appointment Committee; Member, Medicine Hiring Committee; Secretary, CCMG; Member, Accreditation of Centres Committee, CCMG; Member, Education Committee; CCMG, Member Program Committee, CCMG; Secretary, Genetics Society of Canada; Member, Genetics Cell Culture Committee, Lab Proficiency Testing Program; Member, Friends of the History of Sciences Technology and Medicine.

Dr. B. Elliott: Chair, Research and Graduate Studies Committee; Member, Queen's Graduate School Council; Member, Advisory Research Committee; Member, Search Committee for Hematopathology Candidate; Member, PRTCA Committee; MRC Site Visit of Laval University Cancer Centre; Member, Search Committee for Cytogenetics Candidate.

Dr. A. Fletcher: Chairman, Infection Control Committee, Lennox & Addington County General Hospital; Member, Nominating Committee, (Faculty of Health Sciences); Chair, Quality Assurance Committee; Member, Cytology Committee, Laboratory Proficiency Testing Program of Ontario; Member, Cytotechnology Advisory Committee of The Michener Institute for Applied Health Sciences.

Dr. S. Ford: Assistant Dean, Student Affairs, Faculty of Medicine; Member, Promotions and Progress Committee; Member, Phase II Curriculum, Block A Coordinator; Member, Undergraduate Education Committee; Member, PBL Committee; Infection Control Committee Member; Director, Autopsy Service.

Dr. A. Giles: KGH Director, Hemostasis Lab; KGH Director, Hemophilia Program; Member,

Research Policy Committee, HSFO; Member, Thrombosis Interest Group; Chair, Working Party, International Society on Thrombosis & Haemostasis; Co-Chair, Subcmte on Animal Models of Hemorrhagic & Thrombotic Disorders, International Society on Thrombosis & Haemostasis; Member, Subcmte on Anticoagulation, International Society on Thrombosis & Haemostasis; Member, Subcmte for F.VIII/IX, International Society on Thrombosis & Haemostasis; Member, Technology Transfer Board.

Dr. P. Greer: KRCC Research Advisory Committee; Search Committee for Headship (Biochemistry).

Dr. K. Harrison: Fellow, CCMG, Member, American Society for Human Genetics.

Dr. D. Hurlbut: Program Director, Anatomical Pathology; Member, AP Committee; External member, GI Residency Training Program Committee; Medical Audit and Tissue Committee, HDH; AP Weekend Cross Coverage Planning Committee; Ontario Gut Club Meeting.

Dr. R. Kisilevsky: Member, Faculty Board; Member, Scientific Advisory Committee (VIIIth International Symposium on Amyloidosis); Member, Scientific Advisory Committee (Gordon Research Conference); Member, Principal's Advisory Committee (Selection of Head for Anaesthesia); Member, Research Advisory Committee; Member, Medical Biochemistry Study Section, NIH.

Dr. D. LeBrun: Member, Faculty Board; Member, Clinical Teachers Association; Member, Anatomic Pathology Committee; Member, Research Seminar Committee; Member, Search Committee, Pathology; Member, Division of Haematology (Internal Medicine).

Dr. D. Lillicrap: Co-Director of Laboratory, KGH DNA Laboratory; Member, Search Committee for Headship of Diagnostic Radiology; Member, School of Graduate Studies and Research Graduate Council; Member, Blood Utilization Committee, KGH; Member, Research Advisory Committee, Pathology; Treasurer and Executive Committee Member, Association of Hemophilia Clinic Directors of Canada; Chairperson, Steering Group, Association of Hemophilia Clinic Directors of Canada; Member, Expert Advisory Committee on Blood Regulation, Health Canada, Health Protection Branch; Member, DIX Scientific Subcommittee, Association of Hemophilia Clinic Directors of Canada; Chairperson, vonWillebrand Disease Scientific Subcommittee, Association of Clinic Directors of Canada.

Dr. S. Ludwin: Member, University Postgraduate Education Committee; Member, University Equity Issues Committee; SEAMO Staffing Committee; Member, KGH Medical Advisory Committee; KGH Board of Directors; Member, KGH Planning Steering Committee; Member, Department of Pathology Postgraduate Education Committee; Director, Neuropathology Training; Member, Department of Pathology Graduate Committee; Member, Departmental Finance Committee; Member, Pathology Undergraduate Committee; President, Canadian Association of Neuropathologists; Chairman, KGH Credentials Committee; KGH Bioethics Committee; VP, International Society of Neuropathologists; Chair, American Association of Neuropathologists; Chair, KGH Ad Hoc Committee on Image Usage.

Dr. P.N. Manley: Pathologist-in-Chief, HDH/KGH; Chairman, Dept. of Pathology, Queen's; Member, Graduate Committee; Member, Research Advisory Committee; Member, Faculty Council; Member, Faculty Board; Member, SEAMO Governing Committee; Member, SEAMO Finance Subcommittee; Member, Basic Science Heads; Member, Medical Advisory Committee; Member, Medical Advisory Budget Review Committee; Member, Council of Department Heads, Member, CLEO Meetings; Chairman, Departmental Search Committee; Chairman, MD Compensation

Committee Meetings; Member, Lab. Admin. Management Committee; Founding Chairman, WASP; Member CAP (US); Member, International G.I. Club; Member, Ontario Lab Services Review; Member, OMA; Member, College of American Pathologists; Member, Ontario GI Club.

Dr. D.H. Maurice: Member, Council of School Graduate Studies/Research (Dept. of Pharmacology Representative; Member, Research and Graduate Studies Committee; Member, Department of Pharmacology/Toxicology Staff Meetings; and Member, Pathology Staff Meetings; Member, Pathology PRTCA Committee.

Dr. D. Rapson: Member, Breast Site Group, KRCC; Member, Colon Site Group, KRCC; Member and Vice Chair, Pediatric Oncology Program Committee, KRCC; Member, Hematology Resident Training Committee.

Dr. M. Raymond: Chief, KGH Clinical Chemistry; Director, Clinical Chemistry, Belleville General Hospital and L & A County Hospital; Member, KGH Information Systems Steering Committee; Chair, KGH Isotope Committee; Lab. Admin. Management Committee; Member, Conjoint Committee for the Accreditation of Educational Programs in Medical Laboratory Technology - CMA; Chair, Medical Laboratory Program Advisory Committee - St. Lawrence College; President, Ontario Society of Clinical Chemists, Pathology MD Compensation Committee; Member, Lab. End-Users Committee.

Dr. M. Richardson: Director, Electron Microscope Facility.

Dr. J.P. Rossiter: Co-ordinator, Department of Pathology Library; Member, Neuropathology Residency Training Committee; Member, Phase I Curriculum Development Committee.

Dr. C. Rowlands: Laboratory Medical Director, Perth & Smiths Falls Community Hospital; Director, Cytology, KGH/HDH; Member, Search Committee for Hematologist, KGH/HDH; Member, Douglas 2 Renovation Committee; Member, CLEO management Group; Member, Ad Hoc Committee for Consideration of AP Services of KGH.

Dr. S. SenGupta: Medical Director, Kingston Hospitals CLEO; Member, Postgraduate Medical Education Committee; Member, Southeastern Ontario Health Care Network Regional Laboratory Task Force; Member, Hematopathologist Search Committee; Member, MD/PhD Compensation Committee; Chair, CLEO Management Team; Vice President and Executive, OAP; Member, Laboratory Medicine Program Committee, OCTRF; Member, MOH-OAML Fee Schedule Review Committee, OMA; Chair, Tariff Committee, OMA; Member, Test Committee on Laboratory Medicine, RCPS; Member, Examination Board, Certification in Anatomic pathology, RCPS; Chair, Membership Committee, CAP.

Dr. L. Shepherd: Director, Clinical Immunology Lab; Director, Postgraduate Education Committee; Member, Hematologist Search Committee; Member, Hematological Path Training Program; Chair, Section of Hematopathology, Member, Joint Practice for Transplantation and Organ Procurement; Member, Joint Hospital Advisory Committee on HIV Notification of Blood Recipients; Chair, Advisory Committee on Transfusion Medicine; Member, GI Cancer Site Group; Ad Hoc Committee, HDH, Informed Consent for Blood Products; Chair, Coordinating Committee Post Graduate Education; Chair, GP Training Committee; Member, AP Training Committee;

Member, PRTCA Committee; Member, Search Committee; Core lab Working Group; Member, Laboratory Management; Member, Search Committee, Cytogenetics; Member, QA Committee.

Dr. S. Taylor: Co-Director, KGH DNA Laboratory; Member, Faculty of Health Sciences Restructuring Committee, Phase I; Member, Biohazard Safety Committee; Chair, Kingston Regional Cancer Genetics Research Committee; Chair, Working Group on Diagnostic Service, Molecular Genetics; Chair, Ontario Ministry of Health Fellowship Review Committee; Member, Michener Institute Molecular Genetics Post-Diploma Advisory Committee; Member, Ontario Cancer Genetics Network, Lab. Dir. Committee.

Dr. L. Tomalty: Chair, University Biohazard Committee; Member, Technology in Learning Committee; Coordinator, Phase IIA, Faculty of Medicine; Member, Undergraduate Medical Education Committee; Member, Infection Control Committee; Member, Antibiotic Use Subcommittee; Representative, Graduate Council, Microbiology and Immunology; Member, Pathology Postgraduate Education Committee; Member, American Society for Microbiology.

Dr. S. Wasan: Director, Histopathology Lab, HDH; Director, Cytology Lab, HDH; Coordinator, Medical Mortality Conferences; Coordinator, Surgical Mortality Conferences; Coordinator, Paediatric Mortality Conferences; Coordinator, Surgical Pathology Conferences; Acting Director of Laboratories (in Dr. Dexter's absence); and Coordinator, Oral Examination for Residents at HDH; Member, Tissue and Audit Committee; Member (Medical Representative) Quality Circle Committee.

Dr. I. Young: Member, Postgraduate Education Committee; Member, KGH Credentials Committee; Director, Combined Division of Anatomic Pathology, KGH, HDH; Chair, PRTCA Committee.

Dr. D. Zoutman: Associate Director, KGH & HDH Microbiology; Member, Joint KGH/HDH Antibiotic Utilization Committee; KGH Accreditation Committee on Environmental Management; Chairman, Infection Control Committee; Member, Medicine Medical Mortality Committee; Member, Corrections Canada Infectious Diseases Inmate Advisory Committee; President, AMMO; Vice-Chair, Laboratory Medicine Section Council of the Ontario Medical Association; Member and Leader of National Surgical Infection Surveillance Program, Canadian Hospital Epidemiology Committee; Laboratory Surveyor, CAP; Member, Ontario Ministry of Health, Laboratory Services Review Implementation Secretariate, HR; Member, Ontario Ministry of Health Laboratory Services Review Implementation Secretariate, HR; External Reviewer, Laboratory Center of Disease Control; Member, Community and Hospital Infection Control Association of Canada; Member, SPARO, Committee on Surveillance, OMH; Member, LPTP, Bacteriology Committee.

**EDITORIAL BOARDS
AND
GRANT REVIEW COMMITTEES**

OTHER SCHOLARLY ACTIVITY
EDITORIAL BOARDS AND GRANT REVIEW COMMITTEES

(Editorship of a journal, referee for journal or granting body, posters, productions, etc.)

Dr. S. Cole: Member, Medical Research Council of Canada Grants Panel, Cancer "B"; Member, Ontario Graduate Scholarship Selection Panel, Ontario Council on Graduate Studies; Member Canadian Breast Cancer Initiative Review Panel, NCIC; Member, Site Review Team, Laboratory of Nutrition and Molecular Regulation, NCIC.

Dr. C. Collier: CAP Laboratory Inspections (DeGraff Memorial Hospital, MDS Laboratories).

Dr. R. Deeley: Associate Editor, Biochemistry & Cell Biology; Member, NCIC Grants Panel F; Chair, NCIC Grants Panel F. Referee, Biochem. Pharmacol., Cancer Research, European J. Biochem, FASEB, Genomics, Molecular Pharm., JBC; Reviewer, MRC, NCIC, HSFO, UMDI, Canadian Medical Discoveries Fund, McGill University; NSERC, March of Dimes (US), BC Health Care, Alberta Heritage Foundation for Medical Research.

Dr. A.M.V. Duncan: Ad Hoc Reviewer for: Ontario Ministry of Health, Hospital for Sick Children Foundation, MRC, NSERC, Manitoba Health Research Council, BC Health Research Foundation, NHRDP Alzheimer Society, International Journal of Radiation, Mutagenesis, Canadian Journal of Genetics and Cytology, American Journal of Medical Genetics, Cytogenetics and Cell Genetics, Genomics, Genome.

Dr. B. Elliott: USA/MRC Breast Cancer Research Initiative Grant Panel; Reviewer, USA/MRC; Reviewer, MRC Grant Panel; Reviewer, Clinical and Exp. Metastasis, External Reviewer, University of Western Ontario Academic Development Fund.

Dr. S. Ford: Member, Regional AIDS Advisory Committee to Federal Penal Institutions.

Dr. A. Giles: Reviewer for Blood, Thrombosis Research, Thrombosis & Haemostasis, J. Physiology, Canadian Medical Association Journal, Clinical & Investigative Medicine, British Journal of Haematology, Thrombotic and Haemorrhagic Disorders, Medical Research Council of Canada, Heart & Stroke Foundation of Ontario, Physicians' Services Incorporation, Ontario, Canadian Red Cross Blood Transfusion Service, National Health Research & Development Program, Ontario Ministry of Health, Alberta Heritage Foundation, NSERC, PSI and International Society on Thrombosis and Haemostasis.

Dr. P. Greer: External Reviewer, MRC, NCIC, Ontario Thoracic Society, Hospital for Sick Children, Northern Cancer Research Foundation; Member, US Army Medical Research and Materiel Command, Molecular Genetics Panel 1; MRC, Cancer Panel A; External reviewer for Journals Oncogene, Developmental Genetics, Cell Growth and Differentiation and Molecular and Cellular Biology.

Dr. R. Kisilevsky: Editorial Boards for: Amyloid, Int. Rev. Exp. Pathol., Laboratory Investigation; External Referee for Grants: MRC, Alzheimer's Society of Canada, National Institute of Health, USA, Ontario Mental Health Foundation; Referee for Journals: Lab Invest, J. Neurochemistry, Proc. Natl. Acad. Soc (USA), Journal of Rheumatology, J. Clinical Investigation, Scand. J. Immunology, Nature Medicine, Virchows Archives, Am. J. Pathology, J. Immunol., J. Lipid Res., Brain Research, Clin. Immunol. & Immunopathol.

Dr. D. LeBrun: Member, Cancer Research Society, Molecular Biology Panel; Grant Reviewer on the following: Alberta Cancer Board, MRC, NCIC, PSI Foundation, Hospital for Sick Children; Journal Reviewer on the following: BLOOD, Oncogene, American Journal of Pathology.

Dr. D. Lillicrap: Heart and Stroke Foundation of Canada Chairperson of Review Committee VII "Thrombosis and Atherosclerosis"; Reviewer for the following: American Journal of Human Genetics, Human Genetics, British Journal of Haematology, Thrombosis and Haemostasis, Proceedings of the National Academy of Science, Nature Genetics, Blood, Transfusion, Haemophilia, Genomics, J. Clin. Path, Clinical and Lab. Hematology.

Dr. S. Ludwin: Member Editorial Advisory Board, Neuropathology and Applied Neurobiology; Member Editorial Board, Acta Neuropathologica; Member Editorial Board, Glia; Member, Editorial Board, International Journal Surgical Pathology; President, Canadian Association of Neuropathologists; Editorial Board, Int. J. Surgery and Pathology, J. Neuropathology and Experimental Neurology.

Dr. D.H. Maurice: Review Panel Member, Ontario Graduate Studentship; Referee, Medical Research Council; Review Panel Member, Heart & Stroke Foundation of Canada; Referee, Journal of Biological Chemistry; Referee, Molecular Pharmacology; Referee, Can J Physiol Pharmacol.

Dr. M. Richardson: Referee for Atherosclerosis, Experimental Molecular Pathology, Lab. Invest., Circulation.

Dr. L. Shepherd: Executive President, Canadian Association of Hematopathology; Hematopathology Examiner, RCPS; Advisory Group, National Red Cross and Provincial Ministry of Health, Quebec; Advisory Group on the Professional and Technical Issues in Transfusion Medicine, Health Canada; Participant NCIC Tumour Bank Workshop.

Dr. S. Taylor: Grant reviewer for Medical Research Council of Canada and the Alzheimer's Society of Canada.

Dr. L. Tomalty: Referee, Canadian Journal of Microbiology; Examiner, Canadian Society of Laboratory Technologists.


Dr. S. Wasan: Reviewer, Canadian Journal of Ophthalmology, and Archives of Ophthalmology.

Dr. D. Zoutman: Member, Editorial Board, Canadian Journal of Infection Control; Referee, Medical Research Council of Canada Grants Awards; and Referee, Canadian Journal of Infectious

Diseases; Reviewer, Ontario Thoracic Society Grant Awards; Reviewer, Physicians Services Inc. Foundation Grant Award.

COURTESY OF
KGH ARCHIVES

FULL PAPERS PUBLISHED
AND IN PRESS



FULL PAPERS PUBLISHED AND IN PRESS

A.H. Boag. Transforming growth Factor Beta-1 and Matrix Metaloproteinases in Prostatic Adenocarcinoma and Hyperplasia: Coordinated Patterns of Immunohistochemical Expression. *Applied Immunohistochemistry* 5(4):246-251, 1997.

H.E. Feilotter, B. Bergonie, **A.H. Boag**, B. Dorion-Bonnet, B. Duboue, W. Latham, C. Eng, L.M. Mulligan and M. Longy. Loss of Heterozygosity in the Cowden Disease Critical Region in Human Sporadic Breast Carcinoma. *British Journal of Cancer*, August 1997. (Submitted)

H.E. Feilotter, M.A. Nagai, **Boag, A.H.**, C. Eng, and L. Mulligan. Analysis of PTEN and the 10a23 region of Primary Prostate Carcinomas. *Oncogene*. (In Press)

B.G. Campling, L.C. Young, K.A. Baer, Y-M Lam, **R.G. Deeley, S.P.C. Cole** and J.H. Gerlach. Expression of the *MRP* and *MDR1* multidrug resistance genes in small cell lung cancer. *Clin. Cancer Res.* 3: 115-122 (1997).

M. Nakagawa, A. Emoto, N. Nasu, T. Hanada, M. Kuwano, **S.P.C. Cole** and Y. Nomura. Clinical significance of multi-drug resistant associated protein and P-glycoprotein in patients with bladder cancer. *J. Urol.*, 157: 1260-1265 (1997).

B.G. Campling, K.A. Baer, J.H. Gerlach, Y-M Lam, **S.P.C. Cole** and S.E.L. Mirski. Topoisomerase II levels and drug response in small cell lung cancer. *Int. J. Oncol.* 10: 885-893 (1997).

Q. Yu, S.E.L. Mirski, K.E. Sparks and **S.P.C. Cole**. Two COOH-terminal truncated cytoplasmic mutant forms of topoisomerase II α in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing. *Biochemistry* 36: 5868-5877 (1997).

D.W. Loe, R.K. Stewart, T.E. Massey, **R.G. Deeley** and **S.P.C. Cole**. ATP-dependent transport of aflatoxin B₁ and its glutathione conjugates by the product of the *MRP* gene. *Molec. Pharmacol.* 51: 1034-1041 (1997).

H.S.L. Chan, Y. Lu, T.M. Grogan, G. Haddad, D.R. Hipfner, **S.P.C. Cole, R.G. Deeley**, V. Ling and B.L. Gallie. Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein. *Cancer Res.* 57: 2325-2330 (1997).

D.R. Hipfner, K.C. Almquist, E.M. Leslie, J.H. Gerlach, C.E. Grant, **R.G. Deeley** and **S.P.C. Cole**. Membrane topology of the multidrug resistance protein, MRP: A study of glycosylation-site mutants reveals an extracytosolic NH₂-terminus. *J. Biol. Chem.* 272: 23623-23630 (1997).

B.D. Stride, C.E. Grant, D.W. Loe, D.R. Hipfner, **S.P.C. Cole** and **R.G. Deeley**. Pharmacological characterization of the murine and human orthologs of multidrug resistance

protein in transfected human embryonic kidney cells. *Molec. Pharmacol.* 52: 344-353 (1997).

I. Wessel, P.B. Jensen, J. Falck, S.E.L. Mirski, **S.P.C. Cole** and M. Sehested. Loss of amino acids ¹⁴⁹⁰lys-ser-lys¹⁴⁹² in the COOH-terminal region of topoisomerase II α in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization. *Cancer Res.* 57: 4451-4454 (1997).

C.E. Grant, E.U. Kurz, **S.P.C. Cole** and **R.G. Deeley**. Analysis of the intron-exon organization of the human multidrug resistance protein gene (MRP) and alternative splicing of its mRNA. *Genomics* 45: 368-378 (1997).

S.E.L. Mirski, J.H. Gerlach, H.J. Cummings, R. Zirngibl, **P.A. Greer** and **S.P.C. Cole**. Bipartite nuclear localization signals in the C-terminus of human topoisomerase II α . *Exp. Cell Res.* 237: 452-455 (1997).

M.D. Norris, S.B. Bordow, P.S. Haber, G.M. Marshall, M. Kavallaris, J. Madafiglio, S.L. Cohn, H. Salwen, M.L. Schmidt, D.R. Hipfner, **S.P.C. Cole**, **R.G. Deeley** and M. Haber. Evidence that the N-*myc* oncogene regulates *MRP* gene expression in neuroblastoma. *Eur. J. Cancer* 33: 1911-1916 (1997).

H.S.L. Chan, T.M. Grogan, G. Haddad, D.R. Hipfner, **R.G. Deeley** and **S.P.C. Cole**. Standardization of a single-cell assay for sensitive detection of Multidrug Resistance Protein (MRP) expression in normal and malignant cells in archival clinical samples. *J. Lab. Clin. Med.* 130: 297-306 (1997).

R.G. Deeley and **S.P.C. Cole**. Function, evolution and structure of multidrug resistance protein (MRP). *Sem. Cancer Biol.* (*In press, 1997*) (*invited review*)

M. Gao, M. Yamazaki, D.W. Loe, C.J. Westlake, C.E. Grant, **S.P.C. Cole** and **R.G. Deeley**. Multidrug Resistance Protein: Identification of regions required for active transport of leukotriene C₄. *J. Biol. Chem.* (*in revision*).

G.M. Wilson, E.A. Roberts, and **R.G. Deeley**. Low density lipoprotein receptor mRNA stability is modulated by phorbol esters in human liver cell culture models and may involve components of the cytoskeleton. *J. Lipid Res.* 38:437-446, 1997.

R. Saulnier, B. Chan, S. Uniyal, T. Chan, A. Patrzykat, and **B.E. Elliott**. The role of integrins and extracellular matrix in anchorage-independent growth of a mammary carcinoma cell line. *Cell Mol. Biol.* 43(3):455-468, 1997.

R.C. vanWylick, **W.A. Fletcher**, B.B. MacRae and K. Dow. Neonatal Tracheal Obstruction caused by Aspiration of Decidual Tissue. *Pediatrics.* (*In Press*)

G. Ropchan, A. Sanfilippo, **S.E. Ford**. Aortic dissection and the use of the Nicotine Patch. A case Involving a Temporal Relation. *Canadian J. Cardiology* 13(5): 525-528, 1997.

J. Samis, M. Garrett, R.P. Manuel, M.E. Nesheim and **A.R. Giles**. Human Neutrophil Elastase Activates Human Factor V but Inactivates Thrombin-Activated Human Factor V. *Blood* 90:1065-1074, 1997.

A.R. Giles, B. Verbruggen, G.E. Riverad, J. Teitel, I. Walker, and the Association of Hemophilia Centre Directors of Canada. A Detailed Comparison of the Performance of the Standard versus the Nijmegen Modification of the Bethesda Assay in Detecting Factor VIII:C Inhibitors in the Hemophilia A Population of Canada. *Thomb. Haemost.* (In press).

D.E. Bovenkamp and **P. Greer**. A Novel Eph-Family Receptor Tyrosine Kinase is Widely Expressed in the Developing Zebrafish Nervous System. *Developmental Dynamics* 209:166-181, 1997.

R. Kisilevsky. Can Deposition of Amyloid be Prevented in Alzheimer's Disease? *Ann. N.Y. Acad. Sci.* 826:117-127, 1997.

J.B. Ancsin, J.B. and **R. Kisilevsky**. Characterization of High Affinity Binding Between Laminin and the Acute Phase Protein Serum Amyloid A. *J. Biol. Chem.* 272: 406-413, 1997.

E. Lindhorst, A.D. Young, W. Bagshaw, M. Hyland and **R. Kisilevsky**. Acute Inflammation, Acute Phase Serum Amyloid A (SAA) and Cholesterol Metabolism in the Mouse. *Biochim. Biophys. Acta* 1339: 143-154, 1997.

S. Inoue, M. Kuroiwa, K. Ohashi, M. Hara and **R. Kisilevsky**. Ultrastructural Organization of Hemodialysis-associated β_2 -microglobulin amyloid Fibrils. *Kidney Int.* 52: 1543-1549, 1997.

C. Rocken and **R. Kisilevsky**. Binding and Endocytosis of High Density Lipoprotein from Healthy (HDL) and Inflamed (HDL_{SAA}) Donors by Murine Macrophages *In-Vitro*. A Light and Electronmicroscopic Investigation. *Amyloid: Int.J.Exp.Clin.Invest.* 4: 259-273, 1997.

R. Kisilevsky and P.E. Fraser. A β Amyloidogenesis: Unique or Variation on a Systemic Theme? *Critical Reviews in Biochemistry and Molecular Biology* 32:361-404,1997.

D.P. LeBrun, B.P. Matthews, B.J. Feldman and M.L. Cleary. The Chimeric Oncoproteins E2A-PB1 and E2A-HLF are concentrated within Spherical Nuclear Domains. *Oncogene* 15:2059, 1997.

S.K. Ludwin. The Pathobiology of the Oligodendrocyte, *Journal of Neuropathology & Experimental Neurology*, Vol. 56, No. 2, pg. 111-124, February, 1997.

S.C. Brodovsky, M.W. tenHove, R.M.H. Pinkerton, **S.K. Ludwin** and R. Smith. An enhancing optic nerve lesion: malignant glioma of adulthood. *Canadian Journal of Ophthalmology*, 32:409-13, 1997.

S.K. SenGupta, D. More and P.N. Manley. Integrating Academic and Community Laboratory Needs: Developing a Successful Outreach Program. *Clinical Laboratory Management Review*, 11(1):33-38, 1997.

R.J. Rose, H. Liu, D. Palmer and **D.H. Maurice.** Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity. *Br.J.Pharmacol.* 122:233-240, 1997.

M.A. Adams, J.D. Banting, **D.H. Maurice**, A. Morales, A. and J.D.W. Heaton. Vascular control mechanisms in penile erection: Phylogeny and the inevitability of multiple overlapping systems, *Int. J. Impotence Res.*9: 85-91, 1997.

A.S. Hussain, J. Bozinovski, **D.H. Maurice**, McLaughlin, G.S. Marks, J.F. Brien and K. Nakatsu, K. Inhibition of the action of nitric oxide pro-drugs by pyocyanin: Mechanistic studies. *Can. J. Physiol. & Pharmacol.*75:398-406, 1997.

J.S. Elce, P.L. Davies, C. Hegadorn, **D.H. Maurice** and J.S.C. Arthur. The effects of truncation of the small subunit on m-calpain activity and heterodimer formation, *Biochem. J.* 326: 31-38, 1997.

D.H. Maurice. 1997. Cyclic Nucleotide-mediated regulation of vascular smooth muscle cell cyclic nucleotide phosphodiesterase activity: Selective effects of cyclic AMP, *Cell Biochem. Biophys.* (in press).

L.H. Zinman, G. Lawrance, W. Wang, V.M. K. Verge, V.M.K., K.E. Dow, **D.H. Maurice**, P.M. Richardson, R.J. Riopelle, 1997. Collaborative and reciprocal effects of ciliary neurotrophic factor and nerve growth factor on the neuronal phenotype of human neuroblastoma cells, *J. of Neurochem.* (in press).

D. Palmer, K. Tsoi and **D.H. Maurice**, 1997. Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors, *Circ. Res.* (in press).

H. Liu and **D.H. Maurice**, 1997. Regulated expression of cAMP phosphodiesterase 4 (PDE4) in vascular smooth muscle: Differential effects of cAMP on PDE4A, PDE4B, PDE4C and PDE4D, *Circ. Res.* (in press).

A.C. Jackson and **J.P. Rossiter.** Apoptotic cell death is an important cause of neuronal injury in experimental Venezuelan equine encephalitis virus infection of mice. *Acta Neuropathologica* - 93:349-353, 1997.

A.C. Jackson and **J.P. Rossiter.** Apoptosis plays an important role in experimental rabies virus infection. *Journal of Virology* - 71(7):5603-5607, 1997.

J.M. Garrah, M.A. Bisby and **J.P. Rossiter.** Immunolabelling of the cytoplasm and processes of apoptotic facial motoneurons following axotomy in the neonatal rat. *Acta Neuropathologica* (in press).

P.J. Davison, **C.G. Rowlands** and R.C. Cartotto. Dermatofibrosarcoma Protuberans: A Review. Canadian Journal of Plastic Surgery.

E.E. Sterns, **S.K. SenGupta** and B. Zee. Macromolecular Interstitial Clearance, Tumour Vascularity, Other Prognostic Factors and Breast Cancer Survival. Breast Cancer Research and Treatment. 42:113-120, 1997.

K.I. Pritchard, A.H.G Paterson, S. Fine, N.A. Paul, B. Zee, **L.E. Shepherd**, H. Abu-Zahra, J. Ragaz, M. Knowling, M.N. Levine, S. Verma, D. Perrault, P.K.D Walde, V.H.C. Bramwell, M. Poljicak, N. Boyd, D. Warr, B.D. Norris, D. Bowman, G.R. Armitage, H. Weizel, R.A. Buckman. A Randomized Trial of CMF Chemotherapy Added to Tamoxifen as Adjuvant Therapy in Postmenopausal Women with Node Positive Estrogen (ER) and/or Progesterone Receptor (PgR) Positive Breast Cancer: A Report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). J Clin Onc., 15 (6):2302-2311, 1997

M.S. Tallman, J. Anderson, C.A. Schiffer, F.R. Appelbaum, J.E. Feusner, W.B. Woods, A. Ogden, H. Weinstein, **L. Shepherd**, J.M. Rose, P.H. Wiernik, for the ECOG, CALGB, SWOG, CCSG, POG and NCIC-CTG. Phase III randomized study of all-trans retinoic acid (ATRA) vs daunorubicin (D) and cytosine arabinoside (A) as induction therapy and ATRA vs observation as maintenance therapy for patients with previously untreated acute promyelocytic leukaemia. NEJM 337:1021-1028, 1997.

H. Hoag, **S.A.M. Taylor**, **A.M.V. Duncan** and M. Khalifa. Evidence that Skewed X-inactivation is not Needed for the Expression of the Aicardi Syndrome Phenotype. Human Genetics. 100:459-464, 1997.

L. Boccia, J.S. Green, C. Joyce, C. Eng, **S.A.M. Taylor**, and L. Mulligan. Mutation of RET Codon 768 is an accurate Predictor of FMTC Phenotype. Clinical Genetics (in press).

D.R. Siemens, J.C. Nickel and **I.D. Young**. Hemangiopericytoma of the Spermatic Cord. British Journal of Urology (in press).

S. Sharma, A. Humar, **D. Zoutman**, K. Kain. Fatal Falciparum malaria in Canadian travellers. Can. Med. Assoc. J.; 156 (8):1165-1167, 1997.

D. Vukomanovic, **D. Zoutman**, J. Stone, G. Marks, J. Brien, K. Nakatsu. Electrospray mass spectrometric, spectrophotometric and electrochemical methods do not provide evidence for the binding of nitric oxide by pyocyanin at pH 7. Biochem J. 322:25-29, 1997.

D. Vukomanovic, G. van Loon, K. Nakatsu, **D. Zoutman**. Determination of chromium (VI) and (III) by Adsorptive Stripping Voltammetry with Pyrocatechol Violet. Microchem J. 57: 86-95, 1997.

M.E. Ofner-Agostini and Canadian Hospital Epidemiology Committee (includes **D. Zoutman**). Vancomycin-resistant enterococci (VRE) in Canada-Results of the Canadian Nosocomial Infection Surveillance Program 1996 VRE point prevalence surveillance project. *Can. J. Infect. Dis.* 8 (2): 73-78, 1997.

K.R. Forward and the Canadian Piperacillin/Tazobactam Study Group (includes **D. Zoutman**). Study of the comparative activity of piperacillin/tazobactam with currently available antibiotics against 8206 aerobic isolates. *Can. J. Infect. Dis.* 8 (3): 147-153, 1997.

F.G. Hayden and the GG167 Influenza Study Group (includes **D. Zoutman**). Efficacy and safety of the neuraminidase inhibitor zanamavir in the treatment of influenza virus infections. *N. Engl. J. Med.* 337: 874-880, 1997.

D. Zoutman, S. McDonald, D. Vethanayagam. Total and attributable surgical wound infections at a Canadian tertiary care center. *Inf Contr Hosp Epidemiol.* 1997. **(in press)**

Books and Book Chapters

R.G. Deeley and S.P.C. Cole. Multidrug resistance in mammalian cells mediated by members of the ATP-binding cassette superfamily: The P-glycoproteins and MRP. In, *Molecular Genetics of Drug Resistance*, Modern Genetics, Vol. 3, (eds. J.D. Hayes and C.R. Wolf), Chapter 7, pp. 247-298, Harwood Academic, Langhorne, PA. (1997). (*invited*)

S.E.L. Mirski and **S.P.C. Cole.** Multidrug resistance in small cell lung cancer. In, *Drug Resistance in Oncology* (ed. S.D. Bernal), Chapter 2, pp. 27-75, Marcel Dekker, New York. (1997). (*invited*)

R.G. Deeley and S.P.C. Cole. Function, evolution and structure of multidrug resistance protein (MRP). *Sem. Cancer Biol.* (*in press*, 1997) (*invited review*).

L. Tomalty and G. Delisle. CDROM: *Hyperclinic: Interactive Case Studies in Clinical Microbiology*. Wm. C. Brown/McGraw Hill Publishers, ISBN 0-697-38672-4, 1997.

R.C. vanWylick, **W.A. Fletcher**, B.B. MacRae, K. Dow. Neonatal Tracheal Obstruction Caused by Aspiration of Decidual Tissue. *Pediatrics* (*in press*).

P. Ford, **S. Ford.** Cardiovascular Pathology of Phospholipid Antibodies in *Phospholipid Antibodies*, ed. S. Levine.

R. Kisilevsky. 'Amyloidosis' in *Pathology*, 3rd Edition. Ed. Rubin, E. and Farber, J., J.B. Lippincott Co., Philadelphia, 1997 (*in press*)

R. Kisilevsky. 'Animal Models of Amyloid Aggregation and Deposition' in *Progress in Alzheimer's and Parkinson's Diseases*. Eds. Fisher, A., Yorshida, M., and Hanin, I., Plenum Publishing Corporation, New York, 1997 (*in press*)

M.G. Normal and **S.K. Ludwin.** Congenital Malformation of the Nervous System in *General Neuropathology*, D.M. Robertson and R.L. Davis, editors, Williams and Wilkins, 3rd edition, pp 265-329, 1997.

COURTESY OF
KGH ARCHIVES

ABSTRACTS

ABSTRACTS

B.G. Campling, S.R. Wright, S.P.C. Cole, R.G. Deeley and A.H. Boag. Immunohistochemical Detection of the Multidrug Resistance Protein (MRP) in Human Lung Cancer. 8th World Conference on Lung Cancer, August 1997.

A.H. Boag, I.D. Young, M. Weir, P. Kossev, J. Downey and J.C. Nickle. Histologic Prostatic Inflammation does Predict Bacterial Culture or Prostate-Specific Antigen Results. *Modern Pathology* (in press). Presented at the US & Canadian Academy of Pathology, March 1997.

D.R. Hipfner, K.C. Almquist, E. Leslie, M. Gao, **R.G. Deeley and S.P.C. Cole.** Glycosylation and membrane topology of the Multidrug Resistance Protein, MRP. *Proc. Amer. Assoc. Cancer Res.* 38: 2944 (1997).

N. Jain, J.H. Gerlach, L.C. Young, **S.P.C. Cole, R.G. Deeley** and B.G. Campling. Increased expression of a 190 kDa membrane protein in a cisplatin resistant cancer cell line. *Proc. Amer. Assoc. Cancer Res.* 38: 2959 (1997).

D.W. Loe, R.K. Stewart, T.E. Massey, **R.G. Deeley and S.P.C. Cole.** ATP-dependent transport of aflatoxin B₁ (AFB₁) and its glutathione (GSH) conjugates by the multidrug resistance protein, MRP. *Proc. Amer. Assoc. Cancer Res.* 38: 36 (1997). (*recipient of a AACR-AFLAC Young Investigator Travel Award*).

I. Neverova, Y. Canitrot, N.M. Dean, P. Villiet, **R.G. Deeley and S.P.C. Cole.** Reversal of MRP-associated resistance by 2'-modified antisense oligonucleotides. *Proc. Amer. Assoc. Cancer Res.* 38: 2943 (1997).

E.U. Kurz, **S.P.C. Cole and R.G. Deeley.** Comparative analysis of DNA-protein interactions in the 5' flanking region of the multidrug resistance protein (MRP) gene in three small cell lung cancer cell lines. *Proc. Amer. Assoc. Cancer Res.* 38: 3222 (1997).

B.D. Stride, C.E. Grant, D.W. Loe, D.R. Hipfner, **S.P.C. Cole and R.G. Deeley.** Pharmacological characterization of the murine and human Multidrug Resistance Proteins (MRP) in HEK 293 cells. *Proc. Amer. Assoc. Cancer Res.* 38: 2627 (1997).

S.E.L. Mirski, Q. Yu, K. Sparks and **S.P.C. Cole.** Two C-terminal truncated cytoplasmic forms of topoisomerase II α in a VP-16 selected lung cancer cell line result from partial gene deletion and alternative splicing. *Proc. Amer. Assoc. Cancer Res.* 38: 4184 (1997).

C.E. Grant, E.U. Kurz, **S.P.C. Cole and R.G. Deeley.** Analysis of the intron-exon organization of the human Multidrug Resistance Protein (MRP) gene and alternative splicing of its mRNA. *Proc. Amer. Assoc. Cancer Res.* 38: 3221 (1997).

I. Wessel, P.B. Jensen, J. Falck, S.E.L. Mirski, **S.P.C. Cole**, M. Sehested. Alternative splicing leading to deletion of bp 4468-76 coding for lys-ser-lys in topoisomerase II α (topo II) in small cell lung cancer H69/VP cells resistant to etoposide (VP-16) results in an extranuclear enzyme localization. Proc. Amer. Assoc. Cancer Res. 38: 4183 (1997).

D.W. Loe, R.K. Stewart, T.E. Massey, **R.G. Deeley** and **S.P.C. Cole**. ATP-Dependent transport of aflatoxin B₁ and its glutathione S-conjugates by the Multidrug Resistance Protein, MRP. FASEB Advanced Lecture Course "ATP-Binding Cassette (ABC) Transporters: From Multidrug Resistance to Genetic Disease", Gosau, Austria, February 1997.

M. Gao, D.W. Loe, K.C. Almquist, M. Yamazaki, **S.P.C. Cole** and **R.G. Deeley**. Structure and function of human Multidrug Resistance Protein, (MRP). FASEB Advanced Lecture Course "ATP-Binding Cassette (ABC) Transporters: From Multidrug Resistance to Genetic Disease", Gosau, Austria, February 1997. (FASEB Travel Award)

R.G. Deeley and **S.P.C. Cole**. Multidrug Resistance Protein, MRP. FASEB Advanced Lecture Course "ATP-Binding Cassette (ABC) Transporters: From Multidrug Resistance to Genetic Disease", Gosau, Austria, February 1997.

G.M. Marshall, M.D. Norris, S.B. Bordow, P.S. Haber, M. Kavallaris, J. Madafiglio, S.L. Cohn, M.L. Schmidt, D.R. Hipfner, **R.G. Deeley**, **S.P.C. Cole**, M. Haber. Mechanisms of multidrug resistance in neuroblastoma. FASEB Advanced Lecture Course "ATP-Binding Cassette (ABC) Transporters: From Multidrug Resistance to Genetic Disease", Gosau, Austria, February 1997.

S.P.C. Cole and **R.G. Deeley**. Structure/function studies of the multidrug resistance protein, MRP. 6th European ISSX Meeting, Gothenburg, Sweden, June 30, 1997.

P.B. Jensen, I. Wessel, I.J. Falck, S. Mirski, **S.P.C. Cole** and M. Sehested. Sequential co-expression of all 3 multidrug resistance (MDR) phenotypes in a single human small cell lung cancer (SCLC) cell line exposed to etoposide, H69/VP. An illustration of the complex progression of drug resistance. 8th World Conference on Lung Cancer. Dublin, Ireland, August 1997.

S.E.L. Mirski, Q. Yu, K. Sparks and **S.P.C. Cole**. Two C-terminal truncated cytoplasmic forms of topoisomerase II α in the VP-16 selected lung cancer cell line, H209/V6, have lost bipartite nuclear localization signal(s) and result from partial gene deletion and alternative splicing. 8th World Conference on Lung Cancer. Dublin, Ireland, August 12, 1997.

B.G. Campling, N. Jain, **S.P.C. Cole**, **R.G. Deeley** and J.H. Gerlach. Energy dependent reduction of cisplatin accumulation in a cisplatin-resistant human small cell lung cancer (SCLC) cell line. 8th World Conference on Lung Cancer. Dublin, Ireland, August 1997.

S.P.C. Cole and **R.G. Deeley**. Biology of MRP in drug resistance of lung cancer. 8th World Conference on Lung Cancer. Dublin, Ireland, August 14, 1997. (*invited speaker*)

S.P.C. Cole. Drug resistance in lung cancer. Symposium on Lung Cancer - New Aspects. Vienna University, Vienna, Austria, September 22, 1997. (*plenary speaker*)

K.F. Young-Tai, C. Collier, S. Thompson. Monitoring Intravenous Lipid Infusion in Neonates: Triglycerides vs. Turbidity. *Clin. Biochem.* 30(4):378, 1997.

G.J. Delisle and L. Tomalty. Evaluation of an Internet Course for Distance Education. American Society of Microbiology Annual Meeting Miami, 1997.

N. Rahimi, E. Tremblay, R. Saulnier and B.E. Elliott. c-SRC activity is elevated in mammary carcinoma cells co-expressing hepatocyte growth factor (HGF), and HGF receptor and is required for HGF-induced cell growth. Canadian Society for Immunology - Spring 1997 Meeting, Lake Louise, Alberta, March 14-17, 1997.

R. Saulnier, A. Patrzykat, B. Chan, and B.E. Elliott. The role of fibronectin and hepatocyte growth factor in anchorage-independent survival and growth. Canadian Society for Immunology - Spring 1997 Meeting, Lake Louise, Alberta, March 14-17, 1997.

S. Boeters, S. Uniyal, T. Nakamura, B.E. Elliott and B.M.C. Chan. Mouse bone marrow-derived mast cells express the hepatocyte growth factor (HGF) receptor c-met and can modulate HGF activity following activation. Canadian Society for Immunology - Spring 1997 Meeting, Lake Louise, Alberta, March 14-17, 1997.

R. Saulnier, A. Patrzykat, S. Uniyal, T. Chau, B. Chan, and B.E. Elliott. Role of fibronectin and hepatocyte growth factor (HGF) in anchorage-independent growth and survival of a breast carcinoma. 88th Annual Meeting of the American Association for Cancer Research, San Diego, CA, USA, April 12-16, 1997.

B. Elliott, J. Klassen, A. Tuck, A. Boag, B. Bhardwaj, N. Rahimi, B. Campling, S. SenGupta, and E. Sterns. Localization of platelet-derived growth factor β -receptor, hepatocyte growth factor (HGF), and HGF receptor in nonmalignant human mammary tissue and in breast cancer. DOD Era of Hope Meeting, Washington, D.C., November 2, 1997.

B. Elliott, N. Rahimi, E. Tremblay, P. Shenoy, J. Rossiter, and R. Saulnier. Autocrine hepatocyte growth factor-dependent signalling pathways in survival, growth and metastasis of breast carcinoma cells. DOD Era of Hope Meeting, Washington, D.C., November 2, 1997.

R. Saulnier, A. Patrzykat, J. Rossiter, P. Shenoy, B. Chan, and B. Elliott. Hepatocyte growth factor and fibronectin mediate anchorage-independent survival and growth of a murine mammary carcinoma. DOD Era of Hope Meeting, Washington, D.C., November 2, 1997.

D.E. Bovenkamp, P. Greer. Zek1, a Novel Eph-Family Receptor Tyrosine Kinase is Widely Expressed in the Developing Zebrafish Nervous System. 13th Annual Meeting on Oncogenes, National Cancer Institutes in Frederick, MD, June 1997.

J. McVeigh, R. Zirngible, and **P. Greer**. Generation and analysis of Transgenic Mice Expressing a Targeted Inactivating Mutation in the *fps/fes* Proto-oncogene. 13th Annual Meeting on Oncogenes, National Cancer Institutes in Frederick, MD, June 1997.

R. Zirngibl and **P. Greer**. Characterization of the Murine *fps-fex* gene and targeted disruption of the locus. 13th Annual Meeting on Oncogenes, National Cancer Institutes in Frederick, MD, June 1997.

M.A. Cooper, **D.J. Hurlbut**, H. MacDonald, I.T. Beck. Late Onset of Histologically Aggressive Colonic Polyps. *Can. J. Gastroenterol.* 1997;11(Suppl.A); 71A.

K. Chan, **A. Fletcher, D.J. Hurlbut**. A Case of Extra-genital Malignant Mixed Mullerian Tumour: Differential Diagnosis and Literature Review. *Clin. Invest. Med.* 1997;20(4).

M.R. Szewczuk, J. Shearer, B. Hann, W.T. Depew, **D. Hurlbut**. Apoptotic Regulatory Proteins in Normal and Inflamed Intestinal Mucosa. "Selected Topics in GI Disease", Symposium (CAG & Astra), November 1997.

S. Inoue, and **R. Kisilevsky**. Ultrastructure of Isolated Fibrils of Experimental Murine AA Amyloid. Matrix '97: East Coast Connective Tissue Society - XVII Annual Meeting, Boston, MA, March, 1997

S. Inoue, M. Kuroiwa and **R. Kisilevsky**. Ultrastructure and Composition of A β Amyloid Fibrils In-Situ in Alzheimer's Disease. 37th American Society for Cell Biology, Washington, D.C., December 1997

K. Wynd, L. Becker and **D. Lillicrap**. Adenovirus-enhanced receptor-mediated transgene delivery to hepatocytes: Role of the core factor VIII promoter and HNF-1 on transgene expression. Vector Targeting Strategies for Therapeutic Gene Delivery 51, 1997.

A. Keightley, and **D. Lillicrap**. Variation in the von Willebrand factor (VWF) regulatory sequence and its effect on VWF gene expression. *Thrombosis and Haemostasis* 78:364a, 1997.

C. Cameron, C. Notley, S. Hoyle, L. McGlynn, C. Hough, S. Kamisue, **A. Giles** and **D. Lillicrap**. Characterization of the canine factor VIII gene. *Thrombosis and Haemostasis* 78:570a, 1997.

J. Brady, C. Notley and **D. Lillicrap**. Androgen receptor effects on factor IX expression: *in vitro* and *in vivo* studies in mice. *Thrombosis and Haemostasis* 78:572a, 1997.

K. Wynd, L. Becker and **D. Lillicrap**. Adenovirus-enhanced receptor-mediated transgene delivery to hepatocytes: role of the core factor VIII promoter in transgene expression. *Thrombosis and Haemostasis* 78:463a, 1997.

K. Wilton, L-A. MacDonald, J. Brady, M. Begbie, C. Rosenfield and **D. Lillicrap**. Factors influencing variability of the phenotype in haemophilia B Leyden. *Thrombosis and Haemostasis* 78:232a, 1997.

C. Cuthbert and **D. Lillicrap**. The role of GATA and ETS Proteins in regulating megakaryocytic expression of von Willebrand factor. *Thrombosis and Haemostasis* 78:641a, 1997.

S. Kamisue, C. Cameron, C. Notley, L. McGlynn, **A. Giles** and **D. Lillicrap**. A candidate mutation in the factor VIII B domain as a cause of severe canine haemophilia A. *Thrombosis and Haemostasis* 78:923a, 1997.

M. Begbie and **D. Lillicrap**. PAR protein interactions are involved in the transcriptional regulation of the factor VIII and factor IX genes. *Thrombosis and Haemostasis* 78:460a, 1997.

Y-G. Xie, K. Fung, S.F. Hall, **D. Lillicrap** and **S.A.M. Taylor**. Anticipation and lack of association with the HLA locus in Meniere's disease. 47th Annual Meeting. American Society of Human Genetics.

J.A. Dean, M.L. Rand, M.D. Carcao, A.M. Stain, C.R. Sparling, P. Turecek, **D. Lillicrap** and V.S. Blanchette. Diagnosis of definite type 1 von Willebrand disease (VWD): Results of a prospective pediatric study. *Blood* 90:32a, 1997.

K. Mandel, M. Leaker, C. Sparling, A. Poon, **S. Taylor** and **D. Lillicrap**. Activated Protein C resistance screening in children. *Blood* 90:120b, 1997.

D. Kydd and **S.K. Ludwin**. Sympathetic Involvement in HMSN-1a. *Canadian Journal Neurological Sciences*, 1997. (in press)

D. Palmer and **D.H. Maurice**. cAMP-mediated Inhibition of Vascular Smooth Muscle Cell Migration: Role of cAMP-Phosphodiesterases. 37th Annual Meeting of The American Society for Cell Biology, Washington, D.C. December 13-17.

H. Liu and **D.H. Maurice**. Regulation of cAMP phosphodiesterase 4 (PDE4) in Rat Aortic Smooth Muscle Cells: Role of cAMP. 37th Annual Meeting of The American Society for Cell Biology, Washington, D.C. December 13-17.

Y.A. Senis, D. Slack, **J.A. Samis**, **A.R. Giles** and **D.H. Maurice**. Cloning of a Partial cDNA Sequence for Rat von Willebrand Factor (vWF). XVIth Congress of the International Society on Thrombosis and Haemostasis, Florence, Italy, 6-12 June.

A.C. Jackson and **J.P. Rossiter**. Rabies virus infection produces apoptosis. *Neurology* 48 (Suppl.): A162.

J.L. Vanderluit, L.T. McPhail, K.C. Harrington, S. Barclay, L.L. Anderson, **J.P. Rossiter** and W. Tetzlaff. Expression of cell death and survival genes in axotomized facial motoneurons in the adult versus newborn rat. Society for Neuroscience, 27th Annual Meeting - abstract 461.11.

D.W. Kydd and **J.P. Rossiter**. Plasma cell granuloma of the tentorium cerebelli: diagnostic case presentation. Canadian Association of Neuropathologists, 37th Annual Meeting, Ottawa, October 1997.

M. Kimmins, **S.K. SenGupta**, B. Zee, S. Wright, S. Cole and E.E. Sterns. Node-Positive Breast Cancer: biologic Differentiation Between Long-term and Short-term Survival Groups. Presented at 1997 Royal College Annual Meeting. Published in Canadian Journal of Surgery, August 1997.

N. Gill and **S.K. SenGupta**. The Changing Role of the Pathologist. Presented at the 1997 Annual Meeting of the Ontario Association of Pathologists.

C. Erlichman, S. Marsoni, J.F. Seitz, J. Skillings, **L. Shepherd**, B. Zee, C. Milan, L. Bedenne, M. Giovannini, Y.P. Le Truet, V. Torri, B. Tardio, A. Zaniboni, G. Pancera, G. Martignoni, M. O'Connell, M. Kahn, G. Francini. Event free and overall survival is increased by FUFA in resected B colon cancer: a pooled analysis of five randomized trials (RCTS). ASCO 1997 and American Society of Clinical Oncology 33rd Annual Meeting, May 1997, Denver Colorado. Volume 16, 1997.

M.S. Tallman, C.A. Schiffer, F.R. Appelbaum, J.H. Feusner, A. Ogden, **L. Shepherd**, J.W. Anderson, J.M. Rowe, P.H. Wiernik. Incidence and Clinical Course of Patients with Acute Promyelocytic Leukemia Who Develop The Retinoic Acid Syndrome. American Society of Haematology, December 1997.

Trudeau M, Shepherd LE, Riva A. Results of a Phase I Study of Docetoxel and Epirubicin as first line therapy for Metastatic Breast Cancer. San Antonio Breast Cancer Meeting, December 1997. Submitted to ASCO, May 1998.

J.M. Connors, A. Belch, B. Burns, S. Gluck, R. Klasa, R. Meyer, I. Quirt, A. Sadura, C. Sawka, B. Schacter, **L. Shepherd**, A. Smith, B. Zee. Brief VACOP-B followed by High Dose EC+A+GM-CSF for Patients with Poor Prognosis Aggressive Lymphomas. Submitted to ASCO, May 1998.

K.F. Young Tai, **D. Zoutman**, S. McDonald, E. Rivoire. Twelve months surveillance for blood stream infections in babies with lines in a NICU. Poster presented at Annual Meeting of the Canadian Pediatric Society, Halifax, June 1997.

D. Zoutman, J. Gerlach, E. Costello, M. Marmash. Canadian survey of patient teaching strategies to promote adherence to tuberculosis therapy. Poster presented at the Annual Meeting of The International Union Against Tuberculosis and Lung Disease, Chicago, February 1997.

Canadian Hospital Epidemiology Committee (includes **D. Zoutman**). Methicillin-Resistant Staphylococcus aureus (MRSA) in Canadian Hospitals: The first two years of national surveillance. Poster presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), American Society for Microbiology, Toronto, Canada, September 1997, Abstract No. J-112.

Canadian Hospital Epidemiology Committee (includes **D. Zoutman**). Antimicrobial susceptibilities of Canadian isolates of methicillin-resistant Staphylococcus aureus (MRSA), 1995-1996. Abstract presented at Canadian Infectious Diseases Society Annual meeting, Toronto, Canada, September 1997.

Canadian Hospital Epidemiology Committee (includes **D. Zoutman**). Genetic characterization of nosocomial isolates of methicillin-resistant Staphylococcus aureus (MRSA) from across Canada. Poster presented at Annual Meeting of the American Society for Microbiology (ASM), Miami, Florida, May 1997.

D. Zoutman, S. MacDonald, C. Whyman. Cost benefits realized of an active surgical site surveillance program. Poster presented at the annual meeting of the Community and Hospital Infection Control Association of Canada (CHICA), Quebec City, April 1997. *This abstract received awards for best abstract for 1997 and for best abstract by a first time presenter at the CHICA meeting.

E. Costello, **D. Zoutman**, J. Gerlach, M. Marmash. Patient teaching strategies used to promote adherence to tuberculosis therapy. Poster presented at the Annual Meeting of the Canadian Public Health Association, Toronto, Canada, June 1997.

D. Vukomanovic, **D. Zoutman**, J. Stone, G. Marks, J. Brien, K. Nakatsu. Formation of a pyocyanin nitric-oxide adduct at acidic pH. Poster presented at the 40th Annual meeting of the Canadian Federation of Biological Sciences, Quebec City, June 1997.

Canadian Hospital Epidemiology Committee (Includes **D. Zoutman**). Vancomycin resistant enterococci (VRE): Interlaboratory evaluation of the Canadian Nosocomial Surveillance Program (CNISP) point prevalence study. Abstract presented at the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), American Society for Microbiology, Toronto, Canada, September 1997, Abstract No. E-131.

Canadian Hospital Epidemiology Committee (Includes **D. Zoutman**). Central venous associated blood stream infections in Canadian ICU's: Hospital Profile. Abstract presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), American Society for Microbiology, Toronto, Canada, September 1997, Abstract No. J-64.

Canadian Hospital Epidemiology Committee (Includes **D. Zoutman**). Central venous catheter associated blood stream infections in Canadian ICU's: A pilot study. Abstract presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), American Society for Microbiology, Toronto, Canada, September 1997, Abstract No. J-65.

DEPARTMENT OF PATHOLOGY

STATEMENT OF GRANTS AND OTHER ACCOUNTS

1996 - 1997

RESEARCHER	GRANTING AGENCY	AMOUNT
DEELEY, R.	M.R.C.	\$ 92,936.00
COLE, S./DEELEY, R.	M.R.C.	\$115,000.00
COLE,S./DELEY, R.	CENTOCOR	\$ 67,500.00
COLE,S./DEELEY,R.	ISIS	\$ 67,500.00
CAMPLING/GERLACH/ DEELEY	M.R.C.	\$ 39,266.00
ELLIOTT, B.	M.R.C.	\$ 25,800.00
ELLIOTT, B.	CDN.BREAST CANCER	\$ 25,000.00
ELLIOTT, B.	U.S.ARMY	\$106,500.00
ELLIOTT, B.	GENETECH	\$ 13,542.00
ELLIOTT, B.	DONATION	\$ 10,000.00
GILES, A.	HEART & STROKE	\$ 74,855.00
GILES, A.	M.R.C.	\$103,215.00
GILES, A.	BAYER/CDN.RED CROSS	\$ 96,600.00
GILES, A.	BAYER INT.	\$ 97,500.00
GILES, A.	GENETICS THERAPY INC.	\$ 45,630.00
GILES, A.	G.D. SEARLE & CO.	\$ 48,169.00
GREER, P.	LEUKEMIA RESEARCH	\$ 26,400.00
GREER, P.	N.C.I.	\$ 78,194.00
GREER, P.	M.R.C.	\$ 79,000.00
KISILEVSKY, R.	M.R.C.	\$ 97,278.00
KISILEVSKY, R.	NEUROCHEM	\$197,027.00
LEBRUN, D.	HOSP. SICK CHILDREN	\$ 63,979.00

LILICRAP, D.	M.R.C.	\$100,926.00
LILICRAP, D.	HEART & STROKE	\$ 59,973.00
LILICRAP, D.	HEART & STROKE	\$ 66,663.00
LILICRAP, D.	CDN. HEMOPHILIA	\$ 29,160.00
LILICRAP, D./TAYLOR,S.	CLARE NELSON	\$ 5,000.00
LUDWIN, S.	M.R.C.	\$ 62,879.00
MANLEY, P.	HEART & STROKE	\$ 53,250.00
MANLEY, P.	HEART & STROKE	\$ 53,250.00
MANLEY, P.	M.R.C.	\$ 19,350.00
MUELLER, C.	HEART & STROKE	\$ 50,670.00
MUELLER, C.	N.C.I.	\$106,235.00
MULLIGAN, L.	M.R.C.	\$101,125.00
MULLIGAN, L.	CLARE NELSON	\$ 5,000.00
MULLIGAN, L.	N.C.I.	\$ 66,377.00
PETKOVICH, M.	PARKE-DAVIS	\$ 51,909.00
PETKOVICH,M.	M.R.C.	\$ 59,000.00
PETKOVICH,M.	M.R.C.	\$ 67,000.00
RICHARDSON, M.	HEART & STROKE	\$ 69,250.00
ROSSITER, J.	A.L.S.	\$ 35,000.00
SENGUPTA, S.	CLARE NELSON	\$ 6,060.00
TAYLOR, S.	O.C.T.R.F.	\$ 22,939.00
TAYLOR, S.	O.C.T.R.F.	\$ 13,000.00

TOTAL: \$2,674,907.